AWARD NUMBER: W81XWH-14-1-0358 (BC134025)

TITLE: Musculoskeletal Complications and Bone Metastases in Breast Cancer Patients Undergoing Estrogen Deprivation Therapy

PRINCIPAL INVESTIGATOR: Laura E. Wright, Ph.D.

CONTRACTING ORGANIZATION: Indiana University School of Medicine Indianapolis, IN 46202

REPORT DATE: December 2018

TYPE OF REPORT: Final Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**4. TITLE AND SUBTITLE**

Musculoskeletal Complications and Bone Metastases in Breast Cancer Patients Undergoing Estrogen Deprivation Therapy

**14. ABSTRACT**

Between 25-50% of women treated with endocrine therapies develop musculoskeletal toxicities that result in treatment discontinuation. In previous reporting periods, I demonstrated that aromatase inhibitor (AI) treatment caused bone loss and skeletal muscle weakness in mice and that prevention of AI-induced osteoclastic bone resorption using a bisphosphonate attenuated ER-negative breast cancer bone metastases and improved muscle function. These preclinical findings highlight the bone microenvironment as a modulator of tumor growth locally and muscle function systemically. Because muscle weakness is also commonly reported in women treated with selective estrogen receptor modulators (SERMs), during this reporting period I compared musculoskeletal effects of AI with a bone-sparing SERM endoxifen in a non-tumor model. Endoxifen (Endx), an active metabolite of tamoxifen, is currently in phase I trials for ER+ advanced breast cancer and is known of its effects on the musculoskeletal system. Mature female C57BL/6 mice underwent sham surgery or ovariectomy (OVX) and were treated daily with vehicle, the AI letrozole (Let), or Endx. Despite changes in cortical bone deposition, the biomechanical properties of Endx mice relative to OVX mice were significantly improved relative to OVX-vehicle and OVX-Al mice. Muscle-specific force was lower in OVX-Endx mice relative to OVX-vehicle and OVX-Al mice, indicating that SERM-induced muscle weakness is independent of bone resorption.

**15. SUBJECT TERMS**

Breast cancer; bone metastases; estrogen; endocrine therapy; aromatase inhibitors; letrozole; selective estrogen receptor modulators; tamoxifen; endoxifen; bone loss; skeletal muscle; myocyte; bone marrow adipose tissue.

**16. SECURITY CLASSIFICATION OF:**

<table>
<thead>
<tr>
<th>a. REPORT</th>
<th>Unclassified</th>
</tr>
</thead>
<tbody>
<tr>
<td>b. ABSTRACT</td>
<td>Unclassified</td>
</tr>
<tr>
<td>c. THIS PAGE</td>
<td>Unclassified</td>
</tr>
</tbody>
</table>

| 18. NUMBER OF PAGES | 55 |

**19a. NAME OF RESPONSIBLE PERSON**

Laura E. Wright, Ph.D.

E-Mail: laewrig@iu.edu
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Introduction</td>
<td>4</td>
</tr>
<tr>
<td>2. Keywords</td>
<td>4</td>
</tr>
<tr>
<td>3. Accomplishments</td>
<td>4</td>
</tr>
<tr>
<td>4. Impact</td>
<td>23</td>
</tr>
<tr>
<td>5. Changes/Problems</td>
<td>23</td>
</tr>
<tr>
<td>6. Products</td>
<td>24</td>
</tr>
<tr>
<td>7. Participants &amp; Other Collaborating Organizations</td>
<td>25</td>
</tr>
<tr>
<td>8. Special Reporting Requirements</td>
<td>25</td>
</tr>
<tr>
<td>9. Appendices</td>
<td>25</td>
</tr>
</tbody>
</table>
Adjuvant endocrine therapy using an aromatase inhibitor (AI), which drastically depletes peripheral 17β-estradiol (E2) concentrations, is a standard treatment for postmenopausal women with estrogen receptor (ER)-positive breast cancer. Unlike selective estrogen receptor modulators (SERMs), which spare bone, AI treatment leads to severe bone loss and musculoskeletal complications that result in low patient compliance for life-prolonging AI therapy. The mechanism(s) of AI-induced muscular dysfunction have not been identified, however, E2-deprivation is characterized by inflammation and release of systemic factors during bone resorption, which together have been demonstrated in other disease models to cause skeletal muscle weakness through oxidation and nitrosylation of RyR1 and SERCA1, critical calcium channels required for skeletal muscle contraction. What is more, a state of high bone turnover resulting from AI-induced E2 depletion could alter the bone microenvironment by releasing matrix-derived growth factors (e.g., TGF-β) that prime the pre-metastatic niche and increase breast cancer progression in bone. This project was therefore designed to evaluate the effects of AI therapy on the musculoskeletal system in the context of breast cancer by determining 1) how AI-induced E2 depletion impairs muscle function, 2) whether AI-induced E2 depletion increases breast cancer bone metastases and 3) the relative contribution of bone loss in each case. Data obtained during course of the project further our understanding of the mechanism of AI-induced muscle weakness through the identification of genes that contribute to muscle wasting during estrogen deprivation therapy. Furthermore, we compare and contrast the musculoskeletal side effects of AI with the novel SERM endoxifen.

2. KEYWORDS
Breast cancer; bone metastases; estrogen; endocrine therapy; aromatase inhibitors; letrozole; selective estrogen receptor modulators; tamoxifen; endoxifen; bone loss; skeletal muscle; ryanodine receptor; myocyte; bone marrow adipose tissue.

3. ACCOMPLISHMENTS
A. Major scientific goals
Task 1. Determine effects of the aromatase inhibitor (AI) letrozole and the selective estrogen receptor modulator (SERM) endoxifen on skeletal muscle function in vivo.

- A non-tumor in vivo study was carried out to determine the relative effects of letrozole and endoxifen on skeletal muscle function in mature (20-week) female C57Bl/6 mice. Animals were ovariectomized and treated daily with letrozole (10µg/day), endoxifen (1mg/kg/day), bisphosphonate (5µg/kg 3x/week), or sterile PBS (vehicle, 50µL/day). After eight weeks of dosing, the extensor digitalis longus (EDL) muscle was removed by microdissection and tested ex vivo for contractile force. Despite no change in muscle mass in the EDL, gastrocnemius, tibialis anterior, or soleus, EDL muscle-specific force was reduced in mice treated with endoxifen relative to all other treatment groups (Figure 1). To our surprise, letrozole had no effect on muscle-specific force in this non-tumor model of estrogen deficiency. We also observed significant uterine hypertrophy in endoxifen treated mice.
These data indicate that endoxifen may have negative effects on calcium handling, and/or sarcomeric proteins in skeletal muscle via actions on the estrogen receptor (ER)-alpha. Uterine hypertrophy is also likely occurring via agonistic effects on the ER, similar to what is observed in humans.

Following *ex vivo* muscle-specific force measurement, the EDL muscle was flash frozen and RNA was later isolated in order to determine changes in gene expression resulting from endoxifen treatment. These studies revealed that expression levels of the sarcomeric proteins alpha-activin-2 (ACTN2), myozenin-1 (MYOZ1), and titin (TTN) were significantly reduced in muscle following endoxifen treatment (Figure 2). Furthermore, expression levels of the metabolic enzyme pyruvate dehydrogenase E1 beta subunit (PDHB) and the inflammatory factor interleukin-6 (IL-6) were reduced in skeletal muscle isolated from mice treated with endoxifen (Figure 2). These RT-PCR results provide a mechanistic basis for muscle weakness following endoxifen treatment.

Endoxifen, the predominant CYP2D6 metabolite of the selective estrogen receptor modulator (SERM) tamoxifen, is currently being developed as a novel anti-estrogen therapy for the treatment of estrogen receptor (ER)+ breast cancer [clinicaltrials.gov: NCT02311933, NCT01327781, NCT01273168]. Based on our results in Task 1, we conclude that clinicians may need to consider muscle weakness as a side effect of the SERM endoxifen in postmenopausal women. These data therefore contribute to our relatively new understanding of the musculoskeletal effects of endoxifen treatment.

**Task 2. Evaluate biochemical changes in skeletal muscle resulting from estrogen (E2) deprivation therapy.**

In order to assess changes in skeletal muscle at the genomic level in mice treated with the aromatase inhibitor letrozole, RNA was isolated from frozen muscle samples collected from tumor-bearing mice treated with letrozole + the anti-resorptive drug zoledronic acid. In order to gain a holistic picture of drug-induced changes to muscle, genetic markers were selected in the following categories: 1) functional/sarcomeric markers (Figure 3), 2) atrophy/hypertrophy markers (Figure 4), 3) inflammatory markers (Figure 5), 4) and uncoupling protein markers (Figure 5).
Figure 3

Functional/sarcomeric muscle markers

RGY1

Relative Fold change

Relative Fold change

ACVR2A

Relative Fold change

Relative Fold change

NOX-4

Relative Fold change

Relative Fold change

GDF 15

Relative Fold change

Relative Fold change
Figure 3. Atrophy/hypertrophy muscle markers

**Figure 4. Atrophy/hypertrophy muscle markers**

**TRIM 63**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Relative Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-tumor control</td>
<td>0</td>
</tr>
<tr>
<td>Tumor</td>
<td><strong>1</strong></td>
</tr>
<tr>
<td>Tumor + O VX + Let</td>
<td><em>1.5</em></td>
</tr>
<tr>
<td>Tumor + O VX + Let + Zol</td>
<td><strong>2</strong></td>
</tr>
</tbody>
</table>

**TPM 4**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Relative Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-tumor control</td>
<td>0</td>
</tr>
<tr>
<td>Tumor</td>
<td><strong>1</strong></td>
</tr>
<tr>
<td>Tumor + O VX + Let</td>
<td><em>0.5</em></td>
</tr>
<tr>
<td>Tumor + O VX + Let + Zol</td>
<td><strong>1.5</strong></td>
</tr>
</tbody>
</table>

**XIRP 1**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Relative Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-tumor control</td>
<td>0</td>
</tr>
<tr>
<td>Tumor</td>
<td><strong>4</strong></td>
</tr>
<tr>
<td>Tumor + O VX + Let</td>
<td><em>2</em></td>
</tr>
<tr>
<td>Tumor + O VX + Let + Zol</td>
<td><strong>4</strong></td>
</tr>
</tbody>
</table>

**FOXO1**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Relative Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-tumor control</td>
<td>0</td>
</tr>
<tr>
<td>Tumor</td>
<td><strong>15</strong></td>
</tr>
<tr>
<td>Tumor + O VX + Let</td>
<td><em>10</em></td>
</tr>
<tr>
<td>Tumor + O VX + Let + Zol</td>
<td><strong>15</strong></td>
</tr>
</tbody>
</table>

**Nebulin**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Relative Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-tumor control</td>
<td>0.5</td>
</tr>
<tr>
<td>Tumor</td>
<td><em>1.0</em></td>
</tr>
<tr>
<td>Tumor + O VX + Let</td>
<td><em>1.5</em></td>
</tr>
<tr>
<td>Tumor + O VX + Let + Zol</td>
<td><em>1.5</em></td>
</tr>
</tbody>
</table>
RT-PCR results indicated that tumor- and letrozole-induced muscle weakness can largely be attributed to muscle wasting or atrophy (Figure 3) rather than changes to functional proteins in muscle (Figure 4) that lead to calcium mishandling. Additionally, inflammatory or uncoupling markers were largely unaffected (Figure 5), although UCP3 tended to be higher in tumor-bearing and letrozole treated mice. While not statistically significant, these data support clinical findings that exercise capacity is reduced in women with breast cancer undergoing letrozole treatment.

Interestingly, zoledronic acid tended to have positive effects on muscle at the genomic level, supporting the functional data presented in last year’s annual report and published in the resulting Oncotarget manuscript (see appendices) wherein muscle-specific force was improved in zoledronic acid treated mice.

Muscle lysates were also evaluated for changes in the calcium receptor complex RyR1-Calstabin1 by co-immunoprecipitation and western blot (Figure 6). These proteomic data confirmed our RT-PCR data and demonstrated that letrozole treatment was not associated with dissociation or destabilization of the RyR1-complex.
Task 3. Evaluate whether the degree of AI- and SERM-induced muscle weakness correlates with treatment-induced bone loss.

- As demonstrated in the absence of tumor, endoxifen treatment results in reduced muscle specific force in mice (Figure 1). In order to determine whether changes in muscle function correlate with bone loss in our model, we used bone micro-computed tomography (µCT) to measure both trabecular (cancellous) and cortical bone volume and morphology.
- Trabecular bone volume was drastically increased in endoxifen treated mice relative to ovariectomized (OVX) mice treated with or without letrozole (Figure 7). Moreover, microarchitectural parameters including trabecular number, trabecular separation, trabecular thickness, structure model index (SMI), and connectivity density (Conn.D) were also greatly improved. Surprisingly, these effects were more pronounced in endoxifen treated mice than in mice treated with the powerful anti-resorptive agent zoledronic acid.
- Representative images of trabecular bone at the proximal tibia are presented for comparison.
Despite the presence of more bone overall, cortical bone analyses revealed that endoxifen treatment impaired periosteal expansion of bone, resulting in significantly reduced total cross-sectional area and medullary area (Figure 8). These morphological changes in cortical bone ultimately led to reduced polar moment of inertia in endoxifen bones, which indicates that resistance to torsional strain in these bones may be impaired. We postulated that while trabecular/cancellous bone volume and morphology is improved, that changes in cortical bone geometry would likely result in reduced mechanical strength of the bones.
In the final project period, we tested this postulate by analyzing the biomechanical properties of bone using a three-point bending test wherein resistance to fracture can be measured directly and quantitated. These final bone analyses will reveal whether changes observed in the bone \(\mu\)CT parameters translate to biomechanical changes and increase risk of fracture following endoxifen treatment.

Using a three-point bend test, we found that despite a predicted reduced resistance to fracture by bone microCT, the ultimate force, stiffness, and energy to ultimate force were increased in...
femurs of endoxifen treated mice relative to OVX mice dosed with vehicle or letrozole (Figure 9). As expected, letrozole treatment had deleterious effects on the biomechanical properties of bone. The improvement in resistance to fracture in endoxifen treated mice was similar with observed improvements in zoledronic treated mice, the standard of care for postmenopausal osteoporotic women. These surprising results indicate that endoxifen may improve the biomechanics of bone and prevent fracture in postmenopausal breast cancer patients.

**Task 4. Determine whether prevention of osteoclastic bone resorption can ameliorate muscle weakness associated with E2 deprivation in vivo.**

- In order to determine whether inhibition of bone resorption can improve muscle function in E2 deprived mice, non-tumor bearing C57Bl mice were ovariectomized and dosed for eight weeks with vehicle, letrozole, letrozole + zoledronic acid, or endoxifen. Ex vivo muscle-specific force was measured at the termination of the study. Prevention of bone resorption with the anti-resorptive zoledronic acid did not improve muscle-specific force in letrozole treated mice (Figure 10).

- We found no evidence for bone-loss induced muscle weakness in endoxifen treated mice. As demonstrated in Task 3, endoxifen did not result in an elevated state of bone resorption but rather inhibits bone resorption and increases new bone formation through estrogen receptor signaling (Figure 7). Despite this fact, muscle weakness was observed (Figure 10). These findings lead us to postulate that endoxifen-induced muscle weakness is likely due to direct toxic effects on skeletal muscle.

- Furthermore, from a functional standpoint forelimb grip strength was not improved with either zoledronic acid or endoxifen treatment (Figure 11).

- In summary, results from Task 4 indicate that SERMs may induce muscle weakness and that this skeletal muscle side effect is independent of bone loss.
Task 5. Test the direct effects of E2 deprivation therapies letrozole (AI), endoxifen (SERM), and the anti-resorptive therapy bisphosphonate (zoledronic acid) on skeletal muscle *in vitro*.

- We evaluated drug treatments *in vitro* on myocyte differentiation and morphology using murine derived C2C12 myocytes, which when stimulated by differentiation medium containing 2% horse serum, differentiate into myotubes, as pictured:

![C2C12 myocyte differentiation to myotubes](image)

- Results from these studies did not reveal direct effects of zoledronic acid (*Figure 12*), letrozole, or endoxifen on C2C12 differentiation (fusion index) or morphology (fiber diameter).

![Figure 12. C2C12 differentiation was not altered by zoledronic acid treatment](image)

Task 6. Determine the impact of estrogen deprivation therapy (AI and SERM) on the accumulation of bone marrow adipose tissue (MAT), and whether bisphosphonate treatment (zoledronic acid) can prevent MAT accumulation in vivo.
The right tibia was collected from OVX non-tumor bearing mice treated with letrozole, endoxifen, and zoledronic acid. In order to determine the impact of these drug treatments on bone marrow adipose tissue accumulation, bones were scanned by µCT in order to measure total bone marrow volume. After scanning the calcified tissue, bones were decalcified, and stained with osmium tetroxide, a lipid-specific radio-dense compound. Tibiae were then re-scanned by µCT and volumetric quantitation of osmium stained tissue (adipose) was assessed and expressed as a percentage of the total marrow compartment in the proximal tibia region.

OVX-induced infiltration of bone with marrow adipose tissue was blocked by both endoxifen and zoledronic acid treatment, and peripheral adipose tissue assessed by DXA was also reduced in endoxifen treated mice (Figure 13). These data indicate that endoxifen may act on fat directly via the ER.

In line with the marrow and peripheral adipose tissue findings, circulating levels of the adipokine leptin were reduced in endoxifen treated mice (Figure 13).

Results obtained from Task 6 indicate that endoxifen may elicit positive effects on metabolism and adipose depots in the context of estrogen deficiency (OVX).

Task 7. Prepare manuscript containing novel findings from Tasks 1-6.

A manuscript detailing our findings with regard to the effects of letrozole + zoledronic acid or endoxifen on muscle, bone, and adipose tissue is being prepared for publication in the Journal of Bone Oncology.
Task 8. Determine whether the E2 deprivation therapy accelerates the progression of breast cancer bone metastases in vivo.

- As planned, four-week female athymic nude mice underwent OVX or sham surgery and were treated daily with vehicle or AI (10µg/day; n=20/group). Three weeks after surgery and onset of treatment, serum levels of 17beta-estradiol in OVX-AI mice were reduced by 56% (Figure 14, p<0.01; Calbiotech ELISA) and bone mineral density assessed by DXA was also significantly reduced (Figure 14, p<0.01). Furthermore, trabecular bone volume fraction at the proximal tibia was reduced by 67% (Figure 15, p<0.001; SCANCO viva40CT) relative to vehicle-sham and representative images are presented.

- After confirming estrogen deficiency and bone loss, the same animals were inoculated with ER-negative MDA-MB-231 human breast cancer cells into the left cardiac ventricle and followed for cancer progression in bone. Since MDA-MB-231 cells are ER-negative, effects of estrogen deprivation on the tumor should be indirect and attributed to the microenvironment.

![Figure 14. Three weeks post-surgery, serum 17β-estradiol levels were reduced as assessed by ELISA and bone mineral density (BMD) was reduced over time in OVX + letrozole-treated mice.](image-url)
Five weeks after inoculation of MD-MB-231 human breast cancer cells, osteolytic lesion area in bone increased by 110% (Figure 16, p<0.01, X-Ray) and tumor burden in bone assessed histologically was increased by 87% (Figure 17, p<0.01) in OVX-Al mice relative to sham-vehicle.
Furthermore, we found that *ex vivo* maximal contractile force of the extensor digitorum longus muscle was significantly reduced in OVX-AI mice (Figure 18, -12%, p<0.001) relative to sham-vehicle.

Studies in Task 8 confirmed that AI treatment induced bone loss and skeletal muscle weakness, recapitulating effects in cancer patients. As hypothesized, the severe bone loss resulting from AI-induced estrogen depletion may prime the bone microenvironment for the development of breast cancer metastases to bone and potentiate muscle weakness. This model serves as an excellent tool to
study the mechanisms of underlying musculoskeletal defects in cancer patients and to assess potential therapeutics. Studies in Task 9 will evaluate whether protection of bone with bisphosphonates can prevent AI-induced musculoskeletal complications in this model of breast cancer bone metastases.

Task 9. Determine whether prevention of E2 deprivation-induced bone loss can reduce the progression of breast cancer bone metastases in vivo.

OVX mice treated with AI (letrozole; 5mg/kg/d; i.p.) were also treated with the bisphosphonate zoledronic acid (ZA; 0.5 mg/kg/d) and monitored for changes in bone. As anticipated, AI-treated OVX mice lost bone relative to sham-controls, however, bisphosphonate treatment drastically reversed these deleterious effects in bone (Figure 19).

After bone loss was confirmed in OVX-letrozole treated mice, MDA-MB-231 cells were inoculated into the left cardiac ventricle and mice were followed prospectively for changes in body weight and grip...
strength (Figure 20).

Despite no change in body weight or grip strength in bisphosphonate-treated mice, osteolytic lesion area was reduced relative to OVX-letrozole-treated mice and sham-vehicle-treated mice (Figure 21). At the time of sacrifice, ex vivo whole muscle contractility of the EDL was recorded in all treatment groups and cancer-bearing mice with bone metastases had reduced muscle specific force relative to non-tumor control (Figure 21). Bisphosphonates improved muscle contractility.

Figure 20. Following inoculation with breast cancer cells, weight and grip strength declined in cancer-bearing mice and these effects were not reversed by bisphosphonate treatment.

Figure 21. Osteolytic lesion area was increased in estrogen-deprived mice (OVX + letrozole) relative to sham + vehicle treated mice and this effect was reversed by the addition of bisphosphonates.
Task 10. Prepare manuscript containing novel findings from Tasks 8-9.

- The work described in Tasks 8-10 was submitted and accepted for publication in the peer-reviewed cancer research journal *Oncotarget* (see appendices).

B. Training & professional development accomplishments

A major component to this postdoctoral grant involves scientific and professional training in order for me to reach my primary career objective of becoming an independent cancer investigator.

- During the course of the award, I learned the following laboratory techniques, which were required for the successful completion of the aims of this grant:
  1) micro-dissection of skeletal whole muscles from the hindlimbs of mice
  2) isolated whole muscle contractility measurement of the EDL and soleus muscles
  3) hormone and cytokine assays by ELISA
  4) grip strength measurement in mice
  5) subcutaneous injection of drugs in mice
  6) immunoprecipitation of proteins from muscle lysates

- In addition to technical training, I attended career development workshops at both the American Society for Bone and Mineral Research (ASBMR) conference in September 2014 and the Orthopedic Research Society (ORS) conference in August 2015.

- In the summer of 2015, I was selected as a scientific mentor for an undergraduate student through the National Institutes of Health (NIH) Bridges to Baccalaureate Program here at Indiana University. This opportunity was my first chance to serve as a scientific mentor to an up-and-coming scientist. The Bridges to the Baccalaureate program is a collaborative project between Indiana University-Purdue University Indianapolis (IUPUI) and Ivy Tech Community
College of Central Indiana. This NIH-sponsored research program provides underrepresented minority students with experience in sciences within a research community and opens doors for those considering a career in research-related fields. During the eight-week program (June – August 2015), I trained the student in laboratory research techniques, aided in scientific writing, taught the student basic statistical concepts, and provided general college and career guidance.

- The head of the Endocrinology Section in the Department of Medicine nominated me for a promotion to junior faculty at Indiana University in the fall of 2015. The nomination and promotion was awarded in January of 2016, and contributed to my career development in terms of access to faculty resources and privileges (e.g., human tissue bank, seminars, conferences, eligibility for faculty awards, etc.). These resources had an overall positive impact on this DoD project, and certainly on my progression toward becoming an independent cancer researcher.

- In March of 2016, I received the John G. Haddad Young Investigator Award from the American Society for Bone and Mineral Research (ASBMR) for outstanding research in the field of bone.

- As part of my development as primary investigator, I mentored a second-year medical student named Michael Campbell through the Indiana University Student Research Program in Academic Medicine (SRPinAM). During his three months under my wing, I developed a project for him related to his interests in radiation therapy, trained him in the necessary laboratory techniques, and monitored his progress throughout the study. Upon successful completion of the project, he presented his work to peers and researchers associated with the SRPinAM program at Indiana University.

- In March of 2016, I became a member of the Indiana University Simon Cancer Center (IUSCC) where I will be able to make meaningful contributions to research and outreach activities in collaboration with other members. Through the IUSCC, I now have access to its research programs and resources that will support and augment the aims of this grant proposal.

- As part of my development as primary investigator, I mentored a second-year medical student named Gabrielle Duprat through the Indiana University Student Research Program in Academic Medicine (SRPinAM). During her three months under my wing this summer, I developed a project for her related to her interests in diet-induced changes to bone marrow adipose tissue. During the course of the project I trained her in the necessary laboratory techniques and monitored her progress throughout the study. Upon successful completion of the project, she presented her work to peers and researchers associated with the SRPinAM program at Indiana University and won first place in the program’s research competition.

- In June of 2017, I was awarded an American Cancer Society Internal Research Grant ($40,000) for the pursuit of a pilot project focused on how bone marrow adipose tissue affects the tumor microenvironment.

- In September of 2017, I was accepted as a member of the American Association of Cancer Research (AACR).

C. Dissemination of results to communities of interest
Results for these studies were presented by invitation to peers and thought-leaders in the fields of oncology and bone biology at the following national and international research conferences:


**Invited seminars:**
- 08/08/16 Indiana University Simon Cancer Center (IUSCC) Tumor Microenvironment and Metastasis annual retreat, invited seminar, Indianapolis, IN
- 05/15/16 European Calcified Tissue Society (ECTS)/Cancer and Bone Society (CABS), Cancer and Bone Pre-Clinical Day, invited seminar, Rome, Italy
- 03/29/16 Advance in Mineral Metabolism (AIMM) John Haddad Young Investigators Meeting, invited seminar, Snowmass, CO
- 08/03/15 Orthopedic Research Society (ORS) Sun Valley Workshop on Musculoskeletal Biology, Featured Young Investigator, Sun Valley, ID

**Accepted peer-reviewed publications:**
Investigators rely on mouse models to better understand the pathogenesis of skeletal complications of malignancy in order to identify therapeutic targets that may ultimately prevent and treat tumor metastasis to bone. In the process of working on this project, I have learned about the many experimental models of breast cancer bone metastases in use today, each with its own caveats. In collaboration with cancer researchers from around the world, I spearheaded the publication of a methods review article (see appendix) where we described and reported methods for optimizing tumor-take in murine models of bone metastasis. We then provided working protocols for four of the most common xenograft and syngeneic inoculation routes for modeling breast cancer metastasis to the skeleton in mice, including the intra-cardiac method of tumor cell injection utilized in my studies. Recommendations for *in vivo* and *ex vivo* assessment of tumor progression and bone destruction were also provided, followed by discussion of the strengths and limitations of the available tools and translational models that aid investigators in the study of breast cancer metastasis to bone.


**D. Anticipated activities for the next reporting period**
Not applicable
4. IMPACT

Impact of accomplishments on breast cancer field
Results obtained during the granting period were significant for the field of breast cancer metastasis in that they supported the concept that a state of high bone turnover can alter the bone microenvironment to increase the progression of tumor growth at this site. The greater implications for the field are that any treatment or environmental factor that leads to bone loss (e.g., glucocorticoids, GnRH inhibitors, radiation, fracture, osteoporosis, etc.) could increase the homing of dormant disseminated cancer cells to the skeleton. Clinicians thus need to be mindful of bone health in breast cancer patients and survivors.

Additionally, we tested the musculoskeletal side effects of the novel selective estrogen receptor modulator (SERM) endoxifen, which is currently being tested in NCI sponsored trials as an alternative to tamoxifen in the adjuvant setting [clinicaltrials.gov: NCT02311933, NCT01327781, NCT01273168]. Relatively little is known about its impact on the musculoskeletal system. Our data obtained during this reporting period indicate that while endoxifen treatment leads to the accrual of high bone volume, the geometrical arrangement of bone may not be in a biomechanically optimal conformation. Testing of the mechanical properties of bone will be important for determining how endoxifen-induced changes in skeletal morphology and/or bone quality may impact strength and resistance to fracture. Our work is important because it is the first of its kind to demonstrate musculoskeletal side effects of endoxifen. While endoxifen shows promise as a potent anti-estrogen therapy for the treatment of ER+ breast cancer, our studies show that it may be important for clinicians to monitor patients for musculoskeletal side effects that could reduce drug compliance, and/or for morphological changes in bone that increase fracture risk.

Impact on society and public health
Next to nothing is known about the impact that hormone therapies have on muscle function at the cellular and molecular level, despite clinical reports of muscle weakness in patients undergoing AI treatment. Work from this second reporting period investigating this common yet understudied complication of breast cancer treatment revealed that oxidation and nitrosylation of calcium channels in skeletal muscle are likely not the mechanistic basis for AI-induced muscle weakness. If this can be confirmed in future reporting periods, antioxidants may be a viable therapeutic in the prevention or treatment of muscle weakness with AI therapy.

Finally, cancer mortality is typically not caused by growth of the primary tumor, but rather is the result of complications associated with tumor cell metastasis to secondary organ sites including bone. Information obtained from my studies could help guide the selection of therapeutics for breast cancer patients and survivors, with emphasis on the importance of maintaining bone health in order to reduce patient risk of deadly breast cancer bone metastases. The studies presented here address important unanswered clinical questions that have the potential to improve the quality and longevity of life for breast cancer patients.

5. CHANGES/PROBLEMS

Changes in approach and reasoning
Nothing to report

Anticipated problems or delays
Nothing to report

Changes that had a significant impact on expenditures
Nothing to report

Changes in use or care of vertebrate animals
Nothing to report
6. PRODUCTS

Published abstracts:


Peer-reviewed publications:


Book chapter:

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS
Primary investigator (PI): Laura E. Wright, Ph.D. – no change.

8. SPECIAL REPORTING REQUIREMENTS
Nothing to report

9. APPENDICES
See attached documents
Laura E. Wright  
Curriculum Vitae

Assistant Research Professor of Medicine  
Indiana University School of Medicine  
Department of Medicine, Division of Endocrinology  
980 West Walnut Street  
Walther Hall R3, Room #C132  
Indianapolis, IN 46202

OBJECTIVE
My long-term objective is to work as a physician scientist at a top-tier academic research institution where I can positively impact treatment outcomes for cancer patients and make meaningful contributions in oncology research, mentorship, and administrative roles.

EDUCATION
- M.D., Indiana University School of Medicine, Indianapolis, IN – 2022 (anticipated)
- Executive Certificate in the Business of Life Sciences, Kelley School of Business, Indiana University, Bloomington IN – 2015
- Ph.D., Physiological Sciences, University of Arizona, Tucson, AZ – 2012
- M.S., Physiological Sciences, University of Arizona, Tucson, AZ – 2007
- B.S., Human Biology, Biola University, La Mirada, CA – 2005

POSITIONS
2016 – 2018  Assistant Research Professor of Medicine, Department of Medicine, Division of Endocrinology, Indiana University School of Medicine, Indianapolis, IN
2012 – 2015  Postdoctoral Research Fellow, Department of Medicine, Division of Endocrinology, Indiana University School of Medicine, Indianapolis, IN
2006 – 2012  Graduate Research Associate, Department of Medicine, Endocrinology Section, University of Arizona, Tucson, AZ
2005 – 2006  Graduate Research Assistant, McKnight Brain Institute, Neural Systems, Memory and Aging (NSMA), Department of Psychology, University of Arizona, Tucson, AZ
2005 – 2011  Graduate Teaching Assistant, Department of Physiology, University of Arizona, Tucson, AZ

EXPERIENCE AND PROFESSIONAL MEMBERSHIPS
2018  Member, Review Committee for Clinical and Translational Sciences Institute (CTSI), Collaboration in Translational Research (CTR) Pilot Grant Program, Indiana
2017 – present  Member, American Association for Cancer Research (AACR)
2016 – 2018  Member, Indiana University Simon Cancer Center (IUSCC)
2016 – present  Member, Cancer and Bone Society (CABS)
2015 – present  Mentor, National Institutes of Health (NIH) Bridges to Baccalaureate Program, IUPUI, Indianapolis, IN
2007 – present  Member, The American Society for Bone and Mineral Research
2009 – 2010  Member, Graduate Student Library Advisory Council Committee, University of Arizona
2008 – 2009  Member, Recruitment & Admission Committee, University of Arizona, Graduate Interdisciplinary Program in Physiological Sciences

INVITED SEMINARS
08/08/16  Indiana University Simon Cancer Center (IUSCC) Tumor Microenvironment and Metastasis annual retreat, invited seminar, Indianapolis, IN
05/15/16  European Calcified Tissue Society (ECTS)/Cancer and Bone Society (CABS), Cancer and Bone Pre-Clinical Day, invited seminar, Rome, Italy
03/29/16  Advance in Mineral Metabolism (AIMM) John Haddad Young Investigators Meeting, invited seminar, Snowmass, CO
08/03/15 Orthopedic Research Society (ORS) Sun Valley Workshop on Musculoskeletal Biology, Featured Young Investigator, Sun Valley, ID

11/1/13 Indiana University, Tumor Biology Microenvironment Program Seminar Series, Indianapolis, IN

08/14/12 The National Institutes of Allergy and Infectious Diseases (NIAID) Medical Countermeasures Against Radiological Threats (MCART) site visit to Indiana University, invited seminar, Indianapolis, IN

12/12/11 Indiana University, Tumor Biology Microenvironment Program Seminar Series, Indianapolis, IN

12/07/11 Veterans Affairs Medical Center/University of California-San Francisco, Bone Imaging Core, Endocrine Research Unit, San Francisco, CA

07/31/11 The American Society of Pharmacognosy Annual Meeting, Mechanism of Action Series, San Diego, CA

03/07, 11/08, 11/10 Physiological Sciences Student Forum Series Speaker, Arizona Health Sciences Center, University of Arizona, Tucson, AZ

11/04/10 Arizona Physiological Society, Featured Graduate Student Free Communication Lecturer, Midwestern University, Glendale, AZ

TEACHING EXPERIENCE
2009 University of Arizona Undergraduate Department of Physiology, Graduate Teaching Assistant, PSIO 480 “Human Physiology,” Discussion Section Lecturer

2005 – 2007 University of Arizona Undergraduate Department of Physiology, Graduate Teaching Assistant, PSIO 201 and PSIO 202 “Human Anatomy and Physiology,” Laboratory Instructor

2007 Cortiva Institute, Tucson, AZ, ANP 223 “Anatomy and Physiology IV CORE,” Lecturer

HONORS AND AWARDS
2018 Kenneth E. and N. Jeanne Starkey Scholarship for Medical Education, Indiana University School of Medicine

2016 John G. Haddad Young Investigator Award sponsored by Advances in Mineral Metabolism (AIMM) and the American Society for Bone and Mineral Research (ASBMR)

2015 Harold M. Frost Young Investigator Award sponsored by the American Society for Bone and Mineral Research (ASBMR)

2015 National Institutes of Health (NIH) Clinical Loan Repayment Program (LRP) through the National Cancer Institute (NCI)

2014 Department of Defense (DoD) – Breast Cancer Research Program Postdoctoral Fellowship Award (BC134025)

2012 Department of Defense (DoD) – Prostate Cancer Research Program Postdoctoral Fellowship Award (PC101890)

2013 Endocrine Fellows Foundation (EFF)/ASBMR Fellows Forum on Metabolic Bone Diseases award recipient, Baltimore, MD

2013 ASBMR President’s Poster Competition award recipient, Baltimore, MD

2011 National Institutes of Health (NIH) National Graduate Student Research Conference (NGSRC) award recipient, Bethesda, MD

2011 University of California-San Francisco (UCSF), Postdoctoral Bootcamp award recipient

2011 Women in Science and Engineering (WISE) Stipend Award Recipient, University of Arizona, Tucson, AZ

2009 North American Research Conference on Complementary & Integrative Medicine Trainee Travel Award recipient, Minneapolis, MN

2009 American Society of Pharmacognosy Student Travel Award Recipient, Honolulu, HI

2008 Ruth L. Kirschstein National Research Service Award (NRSA) for Individual Predoctoral Fellowship Training (F31, NIH/NCCAM)

2008 Trainee Award Recipient for the Endocrine Society Annual Meeting, Basic Sciences
RESEARCH HIGHLIGHTS

Peer-Reviewed Publications


Abstracts (Presented)


Book Chapter

RESEARCH SUPPORT
Completed Research Support
* BC134025 Wright (PI) 9/2014 – 9/2018
Department of Defense (DoD) – Breast Cancer Research Program $438,833
Musculoskeletal complications and bone metastases in breast cancer patients undergoing estrogen deprivation therapy
The objective of this grant is to evaluate the effects of aromatase inhibitor therapy on the musculoskeletal system by determining how estrogen depletion impairs muscle function and whether estrogen deprivation-induced bone loss can prime the bone microenvironment in ways that increase the progression of breast cancer bone metastases.

- **American Cancer Society (ACS), Internal Research Grant** Wright (PI) 9/2017 – 8/2018
  Indiana University Simon Cancer Center
  *$40,000*
  **Effect of marrow adipose tissue accumulation on breast cancer bone metastases**
  The objective of this project is to measure marrow adipose tissue (MAT)-induced changes in breast cancer growth and invasiveness using *in vitro* and *in vivo* models and to identify probable molecular mechanism(s) by which MAT alters breast cancer cell behavior.

- **IU Health Strategic Research Initiative in Oncology** Wright & Waning (co-PI’s) 11/2013 – 10/2014
  Melvin and Bren Simon Cancer Center, Bio-Plex Core Pilot Project Grant
  *$17,820*
  **Systemic factors responsible for cancer- and cancer therapy-induced ryanodine receptor 1 remodeling and muscle weakness**
  The goal of this project was to identify systemic factors and signaling molecules responsible for maladaptive biochemical modifications to a critical calcium channel in skeletal muscle (RyR1), which leads to muscle weakness during cancer therapy-induced bone loss.

- **PC101890** Wright (PI) 6/2012 – 5/2014
  Department of Defense (DoD) – Prostate Cancer Research Program
  *$123,463*
  **Mechanisms of radiation-induced bone loss and effects on prostate cancer bone metastases**
  The main objective of this study was to elucidate the mechanisms of radiation-induced bone loss and to determine how radiation exposure alters the bone microenvironment to increase the progression of prostate cancer bone metastases.

- **F31 AT004875-04** Wright (PI) 9/2008 – 5/2012
  National Institutes of Health (NIH)
  *$146,588*
  **National Center for Complementary and Alternative Medicine (NCCAM)**
  **Ruth L. Kirschstein National Research Service Award (NRSA)**
  **Ginger extracts in the prevention of metabolic bone disease**
  This was an individual fellowship training grant supporting four years of doctoral training in physiological sciences. Specifically, this grant supported my dissertation research on the bone-sparing effects of natural product-derived compounds in translational models of osteoporosis and lytic breast cancer bone metastases.
LUMINOUS METHODS

Murine models of breast cancer bone metastasis

Laura E Wright¹, Penelope D Ottewell², Nadia Rucci³, Olivier Peyruchaud⁴, Gabriel M Pagnotti⁵, Antonella Chiechi¹, Jeroen T Buijs⁶ and Julie A Sterling⁷,⁸

¹Division of Endocrinology, Department of Medicine, Indiana University, Indianapolis, IN, USA. ²Department of Oncology, Mellanby Center for Bone Research, University of Sheffield, Sheffield, UK. ³Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy. ⁴Physiopathologie, Diagnostic et Traitements des Maladies Osseuses, INSERM, UMR_S1033, Lyon, France. ⁵Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA. ⁶Department of Thrombosis & Hemostasis, Leiden University Medical Center, Leiden, The Netherlands. ⁷Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN, USA. ⁸Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, USA.

Bone metastases cause significant morbidity and mortality in late-stage breast cancer patients and are currently considered incurable. Investigators rely on translational models to better understand the pathogenesis of skeletal complications of malignancy in order to identify therapeutic targets that may ultimately prevent and treat solid tumor metastasis to bone. Many experimental models of breast cancer bone metastases are in use today, each with its own caveats. In this methods review, we characterize the bone phenotype of commonly utilized human- and murine-derived breast cell lines that elicit osteoblastic and/or osteolytic destruction of bone in mice and report methods for optimizing tumor-take in murine models of bone metastasis. We then provide protocols for four of the most common xenograft and syngeneic inoculation routes for modeling breast cancer metastasis to the skeleton in mice, including the intra-cardiac, intra-arterial, orthotopic and intra-tibial methods of tumor cell injection. Recommendations for in vivo and ex vivo assessment of tumor progression and bone destruction are provided, followed by discussion of the strengths and limitations of the available tools and translational models that aid investigators in the study of breast cancer metastasis to bone.

BoneKEy Reports 5, Article number: 804 (2016) | doi:10.1038/bonekey.2016.31

Introduction

Breast cancer metastasis to the skeleton and subsequent bone destruction often result in severe bone pain, fragility fractures, nerve compression syndromes and hypercalcemia of malignancy resulting in significant morbidity and mortality.¹,² Elucidation of the molecular mechanisms that mediate breast cancer bone metastases and cancer-induced bone destruction has begun to reveal potential therapeutic targets that may lead to improved patient survival and quality of life; however, further investigation is necessary to address this currently irreversible late-stage complication of malignancy. Therefore, it is of utmost importance for investigators to establish well-characterized in vivo models of breast cancer bone metastasis.

Unlike the study of postmenopausal osteoporosis where the ovariectomy model is the clear FDA-mandated choice,³ there are numerous murine models of breast cancer metastasis to bone, each with its own benefits and limitations. Because spontaneous metastasis to the skeleton from primary tumors in animals is rare,² and no single model reproduces all of the genetic and phenotypic changes of human breast cancer bone metastasis, researchers must select a model or a combination of models that best suits the aspect of the metastatic disease that they wish to investigate. Here we (1) identify the most commonly utilized breast cancer cell lines that elicit osteolytic, osteoblastic or mixed phenotypes in bone, (2) provide protocols for tumor cell inoculation routes that model breast cancer metastasis to the skeleton in mice and (3) explore methods for the post-inoculation monitoring of breast cancer progression in bone.

Modeling osteolytic breast cancer bone metastases

Inoculation of bone trophic tumor cells directly into the blood stream provides a useful tool for investigating the processes associated with breast cancer cell homing, colonization and subsequent metastatic tumor growth and osteolytic lesion...
formation in bone. Intra-cardiac inoculation of human triple negative MDA-MB-231 adenocarcinoma cells into immune-compromised mice (i.e., BALB/c nude, MF1 nude and NOD/SCID) results in tumor cell dissemination through the arterial vascular system and homing primarily to long bones, spine, jaw and lungs (Figure 1a; Table 1).4,5 In syngeneic tumor models where murine-derived cell lines are inoculated into a murine host, a bone metastatic profile can be observed with varying degrees of success following intra-cardiac injection of 4T1 or PyMT MMTV mammary cancer cells into immune competent BALB/c or FVB/N mice, respectively (Table 1).6,7

Visceral metastases, particularly to the lung, can significantly shorten the life span of a mouse and thus limit the experimental time frame during which skeletal metastases can be studied in vivo. MDA-MB-231 and 4T1 cell lines have therefore been manipulated in the laboratory to produce bone-seeking sub-lines that favor homing to and colonization of mouse tibiae and femurs with a reduced propensity to metastasize to the lung. Bone-seeking sub-lines, often referred to in the literature as MDA-MB-231-B02, MDA-MB-231-1833, MDA-MB-231-B, MDA-IV and MDA-MB-231-bone, form tumors in the long bones of up to 90% of mice following intra-cardiac inoculation in BALB/c nude mice.8–12 Intra-cardiac inoculation of the subline 4T1-2 cells into BALB/c mice results in bone metastases in 70–80% of animals (Table 1).13

Direct intra-tibial injection of a number of breast cancer cell lines including MDA-MB-231, MDA-MB-436 and SUM1315 into immunocompromised mice and 4T1 and PyMT MMTV cell lines into immune competent BALB/c and FVB/N mice results in the development of osteolytic mammary tumors in bone with minimal impact outside of bone marrow engraftment (Figure 1b; Table 1).7,14,15 The intra-tibial model bypasses the early stages of metastasis including homing to the bone microenvironment and is therefore useful for a more direct assessment of tumor–bone interactions, particularly when interested in studying genetic manipulations of the host or tumor cells of interest.

Intra-cardiac, intra-arterial and intra-tibial inoculation of cancer cells provide useful tools for examining the later stages of breast cancer bone metastasis; however, these aforementioned models do not permit investigation into the stages that precede the colonization of breast cancer in bone, including primary tumor growth or the dissemination of tumor cells through intravazation. The 4T1 mouse mammary cancer cell line was derived from a BALB/c spontaneous mammary carcinoma,16 and orthotopic inoculation of 4T1 cells into the

Figure 1  Radiographs of the distal femur and proximal tibia of mice with breast cancer bone metastases. Representative images are presented of (a) MDA-MB-231 breast cancer bone metastases 4 weeks post inoculation of 100 000 cells via intra-cardiac route, (b) ZR-75-1 breast cancer bone metastases 25 weeks post inoculation of 100 000 cells via intra-cardiac route, (c) 4T1 breast cancer bone metastases 4 weeks post inoculation of 10 000 cells via intra-tibial route, and (d) MCF-7 breast cancer bone metastases 20 weeks post inoculation of 100 000 cells via intra-tibial route.
mammary fat pad of BALB/c mice results in spontaneous metastasis to lungs (~60% of mice) and bone (~20–30% of mice; Table 1). Incidence of bone metastasis can be increased to 50–70% by utilizing the bone-seeking 4T1-2 subline. This syngeneic model has the benefit of utilizing an immune competent mouse.

Recently, it was shown that orthotopic inoculation of luciferase-transduced murine invasive lobular breast carcinoma cells (KEP cells) resulted in the formation of bone metastases in the appendicular and axial skeleton within 3 weeks after resection of the orthotopic tumor with minimal lung involvement in BALBc nude mice (Table 1). Although MDA-MB-231 do not metastasize to murine bone from the orthotopic site in BALB/c nude and NOD SCID mice, distant metastases at skeletal sites were observed when using NSG mice, suggesting the importance of NK cells in regulating the metastatic process.

Spontaneous metastasis of an orthotopic human breast cancer tumor to bone can be achieved in an immune-compromised mouse using a unique model that incorporates human-derived bone X-plants. In recent studies, orthotopic inoculation of human-derived SUM-1315 or MDA-MB-231-IV cells into the mammary fat pad of NOD SCID mice 4 weeks following ectopic implantation of human bone resulted in spontaneous metastasis of human breast cancer cells specifically to the human bone grafts in 40–60% of animals (Table 1).

Table 1 Human and mouse mammary cancer cell lines that form osteolytic bone lesions following inoculation into mice

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Species</th>
<th>Origin</th>
<th>Subline</th>
<th>Mouse strain</th>
<th>Inoculation route</th>
<th>Metastatic site(s)</th>
<th>Time to lesion formation</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDA-MB-231</td>
<td>Human</td>
<td>Human mammary adenocarcinoma isolated from a pleural effusion from a 51-year-old Caucasian female</td>
<td>Parental</td>
<td>BALB/c nude MF1 nude NOD/SCID NSG</td>
<td>Intra-cardiac Intra-tibial Orthotopic</td>
<td>Mouse long bones, spine and jaw Mouse long bones, mouse bones Mouse long bones Mouse long bones and jaw 2–3 weeks 1–3 weeks 2 weeks 2–3 weeks</td>
<td>2–3 weeks 1–3 weeks 2 weeks 2–3 weeks</td>
</tr>
<tr>
<td>MDA-MB-231-BO2</td>
<td>Human</td>
<td>Human mammary adenocarcinoma isolated from a pleural effusion from a 43-year-old Caucasian female</td>
<td>Parental</td>
<td>BALB/c nude</td>
<td>Intra-cardiac Intra-tibial Orthotopic</td>
<td>Mouse long bones, mouse bones Mouse long bones Mouse long bones Mouse long bones and jaw 2–3 weeks 1–3 weeks 2 weeks 2–3 weeks</td>
<td>2–3 weeks 1–3 weeks 2 weeks 2–3 weeks</td>
</tr>
<tr>
<td>MDA-MB-231-IV</td>
<td>Human</td>
<td>Human mammary adenocarcinoma isolated from a pleural effusion from a 43-year-old Caucasian female</td>
<td>Parental</td>
<td>BALB/c nude</td>
<td>Intra-cardiac Intra-venous Orthotopic</td>
<td>Mouse long bones, mouse bones Mouse long bones Mouse long bones Mouse long bones Human bone X-plants 2–3 weeks 1–3 weeks 2 weeks 2–3 weeks</td>
<td>2–3 weeks 1–3 weeks 2 weeks 2–3 weeks</td>
</tr>
<tr>
<td>MDA-MB-436</td>
<td>Human</td>
<td>Human mammary adenocarcinoma isolated from a pleural effusion from a 51-year-old Caucasian female</td>
<td>Parental</td>
<td>MF1 nude BALB/c nude NOD/SCID</td>
<td>Intra-osseous</td>
<td>Mouse long bones, mouse bones Mouse long bones Mouse long bones Mouse long bones X-plants 2–3 weeks 1–3 weeks 2 weeks 2–3 weeks</td>
<td>2–3 weeks 1–3 weeks 2 weeks 2–3 weeks</td>
</tr>
<tr>
<td>SUM1315</td>
<td>Human</td>
<td>Isolated from a metastatic nodule of a Caucasian female patient with ductal carcinoma</td>
<td>Parental</td>
<td>NOD/SCID</td>
<td>Intra-tibial Orthotopic</td>
<td>Mouse long bones, X-plants Mouse long bones Mouse long bones Mouse long bones and lungs 2–3 weeks 1–3 weeks 3 weeks 6 weeks</td>
<td>2–3 weeks 1–3 weeks 3 weeks 6 weeks</td>
</tr>
<tr>
<td>4T1</td>
<td>Mouse</td>
<td>Isolated from a stage 1 V mammary tumor from a female BALB/c cIC3H mouse</td>
<td>Parental</td>
<td>BALB/c cIC3H</td>
<td>Intra-cardiac Intra-tibial Orthotopic</td>
<td>Mouse long bones, Mouse long bones Mouse long bones Mouse long bones Mouse long bones and lungs 2–3 weeks 1–3 weeks 3 weeks 4 weeks</td>
<td>2–3 weeks 1–3 weeks 3 weeks 4 weeks</td>
</tr>
<tr>
<td>4T1-2</td>
<td>Mouse</td>
<td>Isolated from a stage 1 V mammary tumor from a female BALB/c cIC3H mouse</td>
<td>Parental</td>
<td>BALB/c cIC3H</td>
<td>Intra-cardiac Intra-tibial Orthotopic</td>
<td>Mouse long bones, Mouse long bones Mouse long bones Mouse long bones Mouse long bones and lungs 2–3 weeks 1–3 weeks 3 weeks 4 weeks</td>
<td>2–3 weeks 1–3 weeks 3 weeks 4 weeks</td>
</tr>
<tr>
<td>PyMT MMTV</td>
<td>Mouse</td>
<td>Induced by MMTV viral oncogene in FVB/N female mouse</td>
<td>Parental</td>
<td>FVB/N</td>
<td>Intra-cardiac Intra-tibial Orthotopic</td>
<td>Mouse long bones, Mouse long bones Mouse long bones Mouse long bones Mouse long bones and lungs 2–3 weeks 1–3 weeks 2 weeks 2–3 weeks</td>
<td>2–3 weeks 1–3 weeks 2 weeks 2–3 weeks</td>
</tr>
<tr>
<td>KEP</td>
<td>Mouse</td>
<td>Mouse invasive lobular carcinoma derived from a Keratin14-driven E-cadherin/p53 (KEP) knock out primary mammary carcinoma</td>
<td>Parental</td>
<td>KEP/Luc RAG-/-; IL2R-/- BALB/c B6 C3H/10T1/2 Luc</td>
<td>Orthotopic Intra-cardiac Intra-tibial Orthotopic</td>
<td>Mouse long bones, Mouse long bones Mouse long bones Mouse long bones Mouse long bones and spine 2–3 weeks 2–4 weeks 6–9 weeks 2–4 weeks</td>
<td>2–3 weeks 2–4 weeks 6–9 weeks 2–4 weeks</td>
</tr>
</tbody>
</table>

Modeling osteoblastic breast cancer bone metastases

Although patients with breast cancer usually develop osteolytic bone metastases, as many as 25% will present with osteoblastic bone metastases. The human breast cancer cell lines ZR-75-1 and MCF-7 can be utilized to establish an osteoblastic bone metastatic phenotype in mice.

ZR-75-1 cultures were initially derived from a malignant ascitic effusion in a 63-year-old Caucasian female with ductal carcinoma. ZR-75-1 cells possess receptors for all four classes of steroid hormones and are thus responsive to estradiol stimulation. Mice inoculated via intra-cardiac route with ZR-75-1 cells develop osteoblastic bone metastases in the long bones; however, bone metastases are typically not detectable by X-ray for 12–25 weeks post inoculation (Figure 1c; Table 2).
Materials and Methods

Table 2 Human mammary cancer cell lines that form osteoblastic bone lesions following inoculation into mice

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Species Origin</th>
<th>Subline</th>
<th>Mouse strain Inoculation route</th>
<th>Metastatic site(s)</th>
<th>Time to lesion formation</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCF-7</td>
<td>Human</td>
<td>Parental</td>
<td>BALB/c nude</td>
<td>Intra-cardiac</td>
<td>Mouse long bones</td>
</tr>
<tr>
<td></td>
<td>Human mammary adenocarcinoma isolated from a pleural effusion in a 69-year-old Caucasian female</td>
<td></td>
<td></td>
<td>Intra-tibial</td>
<td>Mouse tibiae</td>
</tr>
<tr>
<td>ZR-75-1</td>
<td>Human</td>
<td>Parental</td>
<td>BALB/c nude</td>
<td>Intra-cardiac</td>
<td>Mouse long bones and spine</td>
</tr>
</tbody>
</table>

Human MCF-7 breast cancer cells were derived from a metastatic pleural effusion in a 69-year-old Caucasian female with breast carcinoma. neo MCF-7 cells retain characteristics of differentiated mammary epithelium and possess estrogen receptors. Intra-cardiac inoculation of MCF-7 cells in immune-compromised mice results in mixed osteolytic/osteoblastic bone metastases in the long bones after 20–25 weeks (Table 2). In order to speed metastatic progression, the MCF-7 cell line has been stably transfected with the oncogene Neu, and this cell line establishes mixed osteolytic and osteoblastic bone metastases in immunocompromised mice within 10–12 weeks after intra-cardiac inoculation. Because ER + MCF-7 cell growth is estrogen dependent mice should be implanted subcutaneously with slow-release estradiol pellets (0.25 mg) prior to intra-cardiac tumor cell inoculation in order to more closely mimic a pre-menopausal tumor environment and speed the progression of tumor growth in bone. MCF-7 and MCF-7/Neu cells are also commonly utilized to establish bone lesions in mice via the intra-tibial inoculation route, with lesions developing in a shorter time span of 1–3 weeks post injection (Figure 1d; Table 2). Estradiol supplementation is typically not introduced when MCF-7 cells are directly implanted into bone.

Because of volumetric limitations of the mouse circulation 100 μl is the recommended injection volume using the intra-cardiac or intra-arterial routes.

Reagents for tumor cell preparation

(1) PBS (without Ca²⁺ and Mg²⁺)
(2) 0.15% Trypsin EDTA
(3) Cold Dulbecco’s Modified Eagle Medium (or other media) with 10% FBS

Pre-operative management of mice

For the intra-cardiac, intra-arterial and intra-venous metastasis models, mice are inoculated between 4 and 6 weeks of age, as tumor-take is markedly reduced after 6 weeks. For the intra-tibial injection, 6- to 8-week-old mice are typically used, as tibiae of younger mice are small and difficult to inject accurately. A ketamine/xylazine cocktail (100 mg kg⁻¹ and 10 mg kg⁻¹, respectively) or isoflurane (2.5% isoflurane at 2–31 min⁻¹ O₂) may be utilized for anesthesia during the inoculation of tumor cells depending on the laboratory’s preference. Many groups, however, experience improved survival rates following intra-cardiac inoculation with the use of isoflurane (vs ketamine/ xylazine), likely due to increased vascular tone and body temperature. If the mouse strain selected is furred, it may be important to shave the mouse at the site of inoculation for better visualization of anatomical landmarks.

Cellular inoculation routes for modeling breast cancer bone metastases in mice

Intra-cardiac inoculation of breast cancer cells. Once a mouse has been properly anesthetized and is unresponsive to pinch, place it on a sterile surface in supine position ensuring that the vertebral column is straight. Tape the forelimbs away from the torso at a slightly angled and upward position (Figure 2a). Prior to inoculation, clean the chest of the animal thoroughly with betadine and wipe with an alcohol pad or as per the institutional standard operating procedures. Once the chest has been sterilized, gently place one hand on the chest of the mouse to tighten the skin and mark the top of the sternum and the xiphoid process (distal sternum) with a permanent marker (Figure 2a). Make a third mark in the middle of these two landmarks and slightly to your right (animal’s left) just over the heart in the third intercostal space (Figure 2a). This mark identifies the location of the left cardiac ventricle where you will insert the needle for tumor cell inoculation.

With intra-cardiac inoculation, prepare the needle by leaving a small air space in the top of the syringe before slowly drawing up the desired volume of cell suspension into the syringe (Figure 2b). This air space will permit a small influx of bright red oxygenated blood into the syringe hub when properly inserted into the left cardiac ventricle. Hold the skin of the mouse tight with one hand and insert the needle perpendicularly into the middle marking (Figure 2c). When the needle has entered the left cardiac ventricle, watch for the pulse of blood to appear in the hub of the needle. The appearance of air bubbles in the needle hub upon insertion

Materials and Methods

This section begins by detailing recommendations for the preparation of breast cancer cells and pre-operative care instructions for the handling of mice prior to inoculation. Four of the most commonly utilized cell inoculation routes resulting in breast cancer bone metastases are then described, including lists of necessary materials for each technique. Recommendations for the post-inoculation monitoring of animals and assessment of tumor progression in bone in vivo and post mortem are then described.

Breast cancer cell preparation

Manufacturer specifications should guide the user as to the appropriate growth conditions for the cell line of interest. As a general rule for all tumor cell inoculation routes, prepare cells from a fresh batch of low passage number. Split cells 1–2 days prior to the injections such that they reach ~80% confluence on the day of inoculation. Overcrowding of tumor cells can affect their metastatic potential in vivo; therefore, cell confluence prior to inoculation must be monitored judiciously. Wash flasks briefly with the appropriate cold cell culture media or phosphate-buffered saline (PBS), trypsinize (0.15% Trypsin EDTA) at 37°C, and remove cells with ice-cold media containing 10% fetal bovine serum (FBS). Centrifuge (200 g, 5 min) and suspend the cell pellet in ice-cold PBS for quantitation. Re-suspend the cells at the desired concentration (Table 3) in cold PBS and keep the cell suspension for no more than 30 min on ice until the moment of inoculation. Prepare cells in small batches (enough for 1–2 cages or 5–10 animals) and keep on ice to minimize clumping and risk of embolism during the in vivo inoculation.
indicates that it has likely entered the lungs and will need to be removed and repositioned. If you do not see a red pulse of blood in the needle hub but are confident that you are in the correct location, you can pull up slightly on the syringe plunger to verify your position in the cardiac ventricle. If there is still no visible red pulse, the needle can be slowly and slightly adjusted up or down. When small adjustments are futile, remove and reposition the insertion point completely or set the mouse aside temporarily. Extended anesthesia can cause vasoconstriction and reduce the animal’s blood pressure such that the pulse of blood into the needle’s hub becomes less noticeable.

Once the needle is correctly positioned in the left cardiac ventricle, inject the cell suspension slowly into the left ventricle being careful not to move the needle or press it deeper into the thoracic cavity. Keep a close eye on the cell suspension in the syringe and do not inject the air bubble at the top of the syringe (Figure 2b). As soon as the cells have been inoculated, quickly remove the needle, apply slight pressure at the injection site for a few seconds and place the mouse on a heating pad until fully awake. Once mice have fully recovered, monitor their behavior for 24 h and watch for potential signs of embolism or distress.

Materials for intra-cardiac inoculation

(1) Anesthetized mouse (immune compromised if using human cells)
(2) Cellular suspension
(3) 0.5–1 cc insulin syringe, 27–29G, 0.5 inch
(4) Surgical tape
(5) Betadine and alcohol swabs
(6) Permanent marker
(7) Water recirculating heating pad

Intra-arterial inoculation of breast cancer cells in the tail. Once a mouse has been anesthetized with isoflurane, place it on a sterile surface in supine position and tape the torso of the mouse to the table for stability. Use a heating pad or lamp to dilate the vessels within the tail for 2–3 min in order to facilitate greater ease of inoculation. Alternatively, the tail can be placed in warm water (30–35 °C). Using an alcohol pad, disinfect the tail vigorously, which will also help dilate the vessels within the tail and facilitate inoculation. Keep the tail clinched between the forefinger and thumb and insert the needle (beveled edge facing up) horizontally across the proximal section of the tail into the artery (Figure 3). Once the needle has entered the artery, the opposite hand is used to retract the syringe plunger slightly to inspect for a tight fitting within the artery and inspect the barrel of the syringe for a small amount of blood, which should appear at the needle hub. This will not occur if the needle has not breached the epithelial membrane of the artery or if the syringe has protruded through the artery. Once the syringe is properly
inoculate the tumor cell suspension. The fourth mammary gland fat pad is located at the intersection of three prominent blood vessels. After the injection of cells, close the wound with 4–6 unconnected sutures, administer an analgesic as per institutional guidelines and place the mouse on a heating pad until fully awake.

Materials for intra-arterial tail inoculation

(1) Anesthetized mouse (immune compromised if using human cells)
(2) Cellular suspension
(3) 0.5–1 cc insulin syringe, 27–29G, 0.5 inch
(4) Surgical tape
(5) Betadine and alcohol swabs
(6) Water recirculating heating pad

Orthotopic (mammary fat pad) inoculation of breast cancer cells. Place an anesthetized mouse in supine position on a sterile surface and tape the forelimbs and hind limbs away from the torso (Figure 4a). Prior to inoculation, clean the inguinal surface of the animal thoroughly with betadine and alcohol. Using sterile surgical instruments, create a small incision in the skin adjacent to the fourth mammary fat pad (Figures 4b and c). Insert the needle into the fourth mammary gland fat pad and slowly inoculate the tumor cell suspension (Figures 4d and e; Supplementary Video 1). The 4th mammary gland fat pad is located at the intersection of three prominent blood vessels (Figure 4f). As with all techniques, it may be important for investigators to practice and familiarize themselves with the necessary anatomical landmarks prior to initiation of a multi-animal study. After the injection of cells, close the wound with 4–6 unconnected sutures, administer an analgesic as per institutional guidelines and place the mouse on a heating pad until fully awake.

In order to limit the occurrence of spontaneous tumor metastases to the lungs when using murine-derived cells (for example, 4T1), primary tumors can be surgically resected from anesthetized mice when tumors reach ~1 cm³. Animals can then be followed for 3–4 additional weeks for the development of bone metastases.

Some laboratories have reported that orthotopic implantation of the human-derived breast cancer cell lines SUM-1535 and MDA-MB-231-IV into immune-compromised mice can elicit spontaneous metastasis to bone when preceded by engraftment of human bone plugs. In this model, 5 mm bone biopsy cores obtained from human femoral heads (within 2–4 h of removal from the patient) can be implanted under the skin on the posterior surface of the animal prior to tumor cell inoculation in the mammary fat pad. Four weeks after bone plug implantation, the human bone grafts become vascularized and bone marrow resembles that of normal bone. Orthotopic injection of human-derived tumor cells can then proceed as described, and the human bone plugs are then excised at the termination of the study (~8–14 weeks) and evaluated for the presence of breast cancer metastases.

Materials for orthotopic inoculation

(1) Anesthetized mouse (immune compromised if using human cells)
(2) Cellular suspension
(3) 0.1 cc Hamilton syringe, 25–27G, 0.5 inch
(4) Tape
(5) Betadine and alcohol swabs
(6) Sterile scissors and forceps
(7) Suture
(8) Water recirculating heating pad
(9) Analgesic
intra-tibial inoculation of breast cancer cells. Prepare a syringe with the desired tumor cell suspension and set aside until ready to inject. After sterilizing the hind limbs, bend the knee to nearly 90° (Figure 5a). While holding the hind limb between the thumb and index finger, locate the patellar ligament between the knee and the tibia, which should be visible through the skin as a white longitudinal structure. Some laboratories choose to make a 2–3 mm incision through the skin on the knee to more easily visualize the tibia and patellar ligament; however, with practice this may not be necessary. Holding the needle parallel to the tibia in the dominant hand, push the needle through the center of the patellar ligament and into the proximal end of the tibia (Figure 5b). Resistance will be felt once the needle reaches the bone. Twist the needle slightly to drill through the growth plate until the needle can be felt giving way. Once inserted into the bone ∼2–3 mm, attempt to move the needle slightly from side to side. When the needle is in the tibia, it will not be easily moved. If it moves freely from side to side, the needle is most likely embedded primarily in muscle and the insertion will need to be repeated. When the needle is accurately placed inside the narrow cavity of the tibia, inject the cell suspension slowly and then withdraw the needle using the same drilling motion used to enter the bone. In the event that the needle becomes clogged when penetrating or drilling through the top of the tibia, remove the original needle and re-insert a new needle, trying to follow the route created by the first needle. Once complete, use the same technique to inject the contralateral tibia with sterile PBS or desired vehicle to serve as a sham control. Bleeding rarely occurs; however, if blood does appear, apply pressure at the site. Administer an analgesic as per institutional guidelines, place the mouse on a heating pad and monitor until active.

Although cells can be inoculated into the tibia at any age, it is more difficult to penetrate the tibia in older animals once the growth plates have mineralized (>8-week old). On the other hand, very young mice can present injection difficulties due to the small size of the tibia; most laboratories therefore select 4- to 6-week-old mice for the intra-tibial inoculation route. If the mouse strain selected is furred, shave or wet the hair on the hind limb prior to the inoculation in order to better visualize the patellar ligament and other landmarks in the knee.

Materials for intra-tibial inoculation

(1) Anesthetized mouse (immune compromised if using human cells)
(2) Cellular suspension
(3) 0.1 cc Hamilton syringe, 25–27G, 0.5 inch
(4) Betadine and alcohol swabs
(5) Water recirculating heating pad
(6) Analgesic

Assessment of tumor progression in bone

Throughout a bone metastasis experiment, mice should be monitored daily for changes in activity levels, mobility and onset of cachexia, which is a paraneoplastic syndrome characterized in mice by loss of daily for changes in activity levels, mobility and onset of cachexia, throughout a bone metastasis experiment, mice should be monitored. Assessment of tumor progression in bone can be performed using a cabinet X-ray machine (Figure 6a, Table 4). Finally, serum can be assayed for the presence of bone turnover markers, hormones, inflammatory factors or growth factors of interest. When applicable, quantification of spontaneous metastases to lung, liver, brain or adrenals can be performed in paraaffin-embedded organs collected at necropsy. For these analyses, μm sections can be cut every 200 μm through the organ and stained with H&E. The number and area of metastatic foci for each section can then be determined using image analysis software, and results can be expressed as the total metastatic foci number per organ and as total metastatic area per organ.

Discussion

When considering skeletal metastasis models with the intention of studying breast cancer osteolysis, a common choice is the intra-cardiac injection of human breast cancer cells in immune-compromised mice. Alternatively, these human cells can be directly implanted into bone, bypassing earlier steps in the metastatic process. A benefit of the former model is that tumor cells detected in bone have themselves 'seeded the soil,' thus replicating the more natural progression of disseminated tumor cells formation of micrometastases, which progress in size over time, as occurs in humans. The necessity of using immune cell-deficient mice when inoculating human cell lines is typically seen as a limitation because it does not accurately model the immune competent human patient. It can, however, be seen as an advantage, as it eliminates possible confounding effects related to the animal’s immune response and permits the study of human cells in a very permissive host environment.

The pathogenesis of breast cancer bone destruction in the intra-cardiac MDA-MB-231 model is relatively similar to the human condition. Upon inoculation, breast cancer cells circulate in the vasculature, home to the bone compartment, and micrometastases can be detected by BLI in distant skeletal sites as early as 1 week after injection. As the tumor cells proliferate in the bone microenvironment, tumor-derived
Figure 6  The assessment of tumor progression in bone can be carried out by (a) quantitation of osteolytic lesion area by X-Ray, (b) measurement of bone volume fraction (BV/TV) by bone high-resolution microcomputed tomography (μCT), (c) histological assessment of tumor area using hematoxylin/eosin (H&E) staining of long bones and vertebrae and (d) quantitation of tartrate-resistant acid phosphatase (TRAcP) + osteoclasts.
Osteolytic factors stimulate osteoclastic bone resorption and the development of bone lesions, which are quantifiable by X-ray. The most substantial bone destruction tends to occur in the metaphyses of the distal femur and proximal tibia, likely due to the high vascularization and metabolic activity characteristic of these trabecular bone compartments.42

Estrogen receptor (ER)⁺ MCF-7 cells and triple negative MDA-MB-231 cells are two of the most commonly studied human breast cancer cell lines.40 Although ER⁺ primary tumors have a high propensity to metastasize to bone in patients,43 ER⁺ MCF-7 cells are utilized less frequently in models of breast cancer bone metastasis, as tumor-take can be limited using the intra-cardiac inoculation route, and MCF-7 cells require a longer time to develop osteolytic and osteoblastic lesions.44,45 In contrast, ER⁻/C0 MDA-MB-231 cells readily metastasize to bone and develop osteolytic lesions as early as 2–3 weeks post inoculation.39 In defense of the use of an ER⁻ cell line, it should also be noted that there is a large discordance between the ER status of primary tumors and the ER status of the bone metastatic tumors in patients.43

The intra-tibial inoculation method is ideal for modeling the final stages of breast cancer bone metastasis and for studying direct interactions between tumor cells and the bone micro-environment without concerns about differential tumor-take from animal to animal. Murine-derived 4T1 cell proliferation in the tibia and subsequent development of osteolytic lesions can occur with the injection of as few as 10 000 murine-derived cells. At higher cellular concentrations (50 000–200 000 cells), our laboratories have observed 4T1 cell metastasis to contralateral tibiae, femurs, forelimbs and the lungs, often limiting the duration and utility of the model. As with all techniques presented here, it is recommended that investigators thoroughly characterize their cell line and inoculation route of choice by conducting dose–response studies in order to establish the optimal protocols prior to embarking on large animal trials.

Inoculation of cancer cells into the tail vein is a well-established bone metastasis model for multiple myeloma.46,47 Our laboratories and others have found that the injection of breast cancer cells into the tail vein results almost exclusively in lung metastases, with limited tumor-take in bone.22,48 When skeletal metastases are desired, we therefore recommend utilization of the tail artery as the tumor inoculation route for breast cancer models.22,48–52

In addition to specific limitations related to model choice discussed above, standard methodologies used by bone metastasis researchers to assess bone destruction and tumor burden have their own limitations. Osteolytic lesion area and tumor burden area in bone are typically assessed by measurement of X-Ray scan or by serial histological sectioning, respectively, and are thus merely two-dimensional approximations of three-dimensional tumors. Improvement in imaging has enhanced sensitivity of detection and yields more accurate

---

**Table 3** Preparation of breast cancer tumor cells for inoculation in mice

<table>
<thead>
<tr>
<th>Inoculation route</th>
<th>Cell number</th>
<th>Volume (PBS)</th>
<th>Syringe/needle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intra-cardiac</td>
<td>100 000</td>
<td>100 µl</td>
<td>0.5–1 cc insulin/27–29G, 0.5 inch</td>
</tr>
<tr>
<td>Intra-arterial (tail)</td>
<td>100 000</td>
<td>100 µl</td>
<td>0.5–1 cc insulin/7–29G, 0.5 inch</td>
</tr>
<tr>
<td>Orthotopic</td>
<td>100 000–5 00 000</td>
<td>10–20 µl</td>
<td>0.1 cc Hamilton/25–27G, 0.5 inch</td>
</tr>
<tr>
<td>Intra-tibial</td>
<td>10 000–2 50 000</td>
<td>10–20 µl</td>
<td>0.1 cc Hamilton/25–27G, 0.5 inch</td>
</tr>
</tbody>
</table>

---

**Table 4** Principal end points used to characterize the development of bone metastases in mice

<table>
<thead>
<tr>
<th>Type</th>
<th>Endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In vivo analyses</strong></td>
<td></td>
</tr>
<tr>
<td>Activity levels and hind limb mobility</td>
<td>Daily</td>
</tr>
<tr>
<td>Respiratory distress</td>
<td>Daily</td>
</tr>
<tr>
<td>Symptoms of cachexia</td>
<td>Daily</td>
</tr>
<tr>
<td>X-ray analysis of osteolytic lesions</td>
<td>Weekly or bi-monthly</td>
</tr>
<tr>
<td>Bioluminescence imaging (BLI; if applicable)</td>
<td>Weekly or bi-monthly</td>
</tr>
<tr>
<td><strong>Post-mortem analyses</strong></td>
<td></td>
</tr>
<tr>
<td>Gross dissection</td>
<td>Inspection for visceral metastases in lung, liver, adrenals and brain tissue</td>
</tr>
<tr>
<td>Bone microcomputed tomography (µCT)</td>
<td>Trabecular bone volume/total volume (BV/TV) of the proximal tibia, distal femur and lumbar vertebrae</td>
</tr>
<tr>
<td>Histomorphometric analysis of bone</td>
<td>Tartrate-resistant acid phosphatase (TRAcP) staining of bone</td>
</tr>
<tr>
<td></td>
<td>Osteoclast number/bone surface (OcN/BS)</td>
</tr>
<tr>
<td></td>
<td>Osteoclast surface/bone surface (OcS/BS)</td>
</tr>
<tr>
<td></td>
<td>Osteoclast number at the bone–tumor interface</td>
</tr>
<tr>
<td>Tumor characterization</td>
<td>Hematoxylin/eosin (H&amp;E) staining of bone for BV/TV and osteoblast number/bone surface (ObN/BS)</td>
</tr>
<tr>
<td></td>
<td>Immunohistochemical staining for proteins of interest (e.g., cytokeratin, phospho-smads)</td>
</tr>
<tr>
<td></td>
<td>H&amp;E staining of visceral organs for quantitation of soft tissue metastases</td>
</tr>
<tr>
<td>Serum factors</td>
<td>Biomarkers, if applicable (e.g., bone turnover markers, hormones, inflammatory factors, growth factors, tumor-derived factors)</td>
</tr>
</tbody>
</table>

---
quantification of metastases. Typically, BLI using codon-optimized luciferase-labeled cells yields higher detection than fluorescent imaging using GFP-labeled cells. Small animal imaging of bone has forged ahead with the development of high-resolution in vivo CT scanners in combination with BLI. However, the bone metastasis research community has been slower to adopt such methodologies. One reason for this is that cumulative radiation exposure from CT scanners has been found to enhance metastases and thus could confound cancer metastasis models if radiation exposure is not monitored judiciously.

Despite their limitations and caveats, the established murine models of breast cancer bone metastases have proven to be excellent tools for the study of bone and cancer cross talk and for the evaluation of potential therapeutics that prevent cancer progression and disrupt the cycle of bone destruction driven by metastasis.

Multimedia

The following article documents and visually demonstrates intra-cardiac and intra-tibial inoculation of cancer cells in mice and also demonstrates representative experimental end points of bone metastasis: http://www.jove.com/video/4260.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

We thank Alyssa Merkel and Kristin Kwakwa for capturing the photographs in Figures 2 and 5 and Johnny Ribeiro and Khalid Mohamad for their technical input on the orthotopic and photographs in Figure 3. We thank Mohammad S. Pe’cheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Anbalagan A, Olabi MB and Celli J. Bynai D for their technical input on the orthotopic and photographs in Figure 3. We thank Mohammad S.

References


Supplementary Information accompanies the paper on the BoneKEy website (http://www.nature.com/bonekey)
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo

Laura E. Wright1, Ahmed A. Harhash1, Wende M. Kozlow2, David L. Waning3, Jenna N. Regan1, Yun She1, Sutha K. John1, Sreemala Murthy1, Maryla Niewolna1, Andrew R. Marks4, Khalid S. Mohammad1, Theresa A. Guise1

1 Department of Medicine, Division of Endocrinology, Indiana University, Indianapolis, IN, USA
2 Department of Internal Medicine, Division of Endocrinology, University of Virginia, Charlottesville, VA, USA
3 Department of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, Hershey, PA, USA
4 Department of Physiology, Columbia University, New York, NY, USA

Correspondence to: Laura E. Wright, email: laewrig@iu.edu

Keywords: breast cancer, bone, metastasis, aromatase inhibitor, skeletal muscle

Received: October 20, 2016 Accepted: November 23, 2016 Published: December 25, 2016

ABSTRACT

Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We hypothesized that AI-induced bone loss could increase breast cancer progression in bone and exacerbate muscle weakness associated with bone metastases. Female athymic nude mice underwent ovariectomy (OVX) or sham surgery and were treated with vehicle or AI (letrozole; Let). An OVX-Let group was then further treated with bisphosphonate (zoledronic acid; Zol). At week three, trabecular bone volume was measured and mice were inoculated with MDA-MB-231 cells into the cardiac ventricle and followed for progression of bone metastases. Five weeks after tumor cell inoculation, tumor-induced osteolytic lesion area was increased in OVX-Let mice and reduced in OVX-Let-Zol mice compared to sham-vehicle. Tumor burden in bone was increased in OVX-Let mice relative to sham-vehicle and OVX-Let-Zol mice. At the termination of the study, muscle-specific force of the extensor digitorum longus muscle was reduced in OVX-Let mice compared to sham-vehicle mice, however, the addition of Zol improved muscle function. In summary, AI treatment induced bone loss and skeletal muscle weakness, recapitulating effects observed in cancer patients. Prevention of AI-induced osteoclastic bone resorption using a bisphosphonate attenuated the development of breast cancer bone metastases and improved muscle function in mice. These findings highlight the bone microenvironment as a modulator of tumor growth locally and muscle function systemically.

INTRODUCTION

Breast cancer is the most commonly diagnosed cancer in women [1] and the majority of breast tumors are hormone-responsive [2]. Adjuvant endocrine therapies that impair the action of estrogen on breast tissue have become an important treatment strategy, reducing the risk of recurrence and death in women with estrogen receptor (ER)-positive disease [3-5]. Aromatase inhibitors, which block the rate-limiting step of estrogen biosynthesis [6], have replaced selective estrogen receptor modulators (SERMs; e.g., tamoxifen) as the standard of care in postmenopausal breast cancer patients due to improved disease-free survival [7, 8]. AI treatment regimens in the adjuvant setting are typically administered for five years and the extension of AI treatment regimens to ten years is
that estrogen deprivation therapy results in a high bone turnover state that increases breast cancer bone metastases and is a strong systemic increase in oxidative stress and inflammatory tone [22]. The second aim of our study was to assess the role of AI therapy-induced bone loss on the progression of disseminated breast cancer cells in vivo.

The impact of AI therapy on skeletal muscle function at the cellular and molecular level remains unknown despite clinical reports of muscle fatigue in AI-treated patients [10-13]. Because the bone matrix can be a source of growth factors, including members of the transforming growth factor (TGF)-β superfamily that affect both bone and muscle [23, 24], a state of high bone turnover can cause release of growth factors into circulation where they act on peripheral tissues. Previous studies in our laboratory have demonstrated that bone-derived TGFβ leads to oxidative overload in neighboring skeletal muscle and impaired muscle contractility in mice with osteolytic bone metastases [25]. The second aim of this study was to evaluate the effect of AI therapy and bone loss on skeletal muscle function in mice with bone metastases.

The overarching hypothesis driving this work is that estrogen deprivation therapy results in a high bone turnover state that increases breast cancer bone metastases and potentiates muscle weakness. It is important to note that we selected a triple negative breast cancer cell line (MDA-MB-231) in order to examine microenvironment-specific effects on tumor growth in the absence of direct effects of inhibition of ER signaling. Here we report that AI treatment causes bone loss and skeletal muscle weakness in OVX mice, and that the prevention of osteoclastic bone resorption attenuates the development of ER-negative breast cancer bone metastases and improves muscle function in AI-treated estrogen-deprived mice.

RESULTS

Aromatase inhibitor treatment reduced serum 17β-estradiol and trabecular bone volume in OVX nude mice prior to tumor inoculation

Four-week female athymic nude mice underwent ovariectomy (OVX) or sham surgery and were treated via daily subcutaneous injection with vehicle (PBS, 50μL), or the aromatase inhibitor letrozole (Let, 10μg/d) (Figure 1). A sham-Let group was included as an experimental control in order to assess potential direct effects of letrozole on muscle function in the presence of ovarian estrogen production. A second OVX-Let-treated group was treated with the bisphosphonate zoledronic acid (Zol, 5μ/kg 3x/week) in order to determine the relative importance of bone loss on tumor growth and muscle function in the setting of AI therapy (Figure 1). Prior to the inoculation of tumor cells and three weeks after surgery, serum 17β-estradiol was reduced in OVX-Let and OVX-Let-Zol mice relative to sham groups (Figure 2A). A partial reduction in serum estradiol was observed in OVX-PBS-treated mice relative to sham, although this did not reach statistical significance (Figure 2A). As a terminal and surrogate measure of estrogenic activity [26], uterine weight was recorded at the end of the study (nine weeks post-surgery and five weeks after tumor inoculation). As anticipated, OVX resulted in significant uterine atrophy relative to sham groups regardless of drug treatment, and the addition of aromatase inhibitor to ovary intact mice (sham-Let) resulted in a moderate reduction in uterine weight relative to sham-PBS, though this did not reach statistical significance (Figure 2B).

In line with observed estrogenic changes, trabecular bone volume (BV/TV) assessed by bone microcomputed tomography was reduced in sham-Let and OVX-PBS mice (-29% and -52%, respectively) relative to estrogen-replete sham-PBS controls (Figure 3A). The combination of OVX and letrozole (OVX-Let) resulted in 67% reduction in trabecular bone volume relative to sham-PBS mice (Figure 3A). The anti-resorptive zoledronic acid increased trabecular bone volume in the OVX-Let-Zol mice by over three times that of sham-PBS mice and over ten times that of OVX-Let mice after three weeks of treatment (Figure 3A). Bone microarchitectural parameters, including connectivity density, structure model index, and trabecular number, separation and thickness, mirrored changes observed in trabecular bone volume for all treatment groups (Figure 3B-3G). In summary, each microarchitectural property assessed was severely compromised in OVX-Let mice relative to estrogen-replete sham-PBS mice and these maladaptive changes were completely reversed by the addition of letrozole.
modifications in trabecular bone were significantly improved by zoledronic acid treatment (Figure 3B-3G).

**Osteolysis and tumor burden were increased in aromatase inhibitor-treated OVX mice**

Having established an estrogen deficiency-driven high bone turnover state in OVX-Let mice by week three, MDA-MB-231 human breast cancer cells were inoculated into the left cardiac ventricle to generate a model of breast cancer metastatic to bone in order to determine the importance of aromatase inhibitor-induced changes to the bone microenvironment on tumor progression in the skeleton. Weekly body weight measurements were performed as a general assessment of disease progression and overall health [27]. For the duration of the study, OVX-Let-Zol mice maintained a higher average absolute body weight, achieving statistical significance relative to sham-Let and OVX-Let animals (Figure 4A). Body composition analyses by dual energy X-ray absorptiometry (DXA) revealed similar patterns of change in lean mass and fat mass percentage over time between groups, with differences observed only in fat mass percentage at week nine between OVX-Let-Zol and sham-PBS-treated mice (Figure 4B, 4A). The rapid decline in total body weight, lean mass, and fat mass observed in all treatment groups at week six (three weeks post-tumor inoculation) (Figure 4A-4C) is indicative of tumor progression in this model [27].

Changes in bone mineral density (BMD) following the inoculation of tumor cells were assessed by DXA over time. Consistent with the observed increase in trabecular bone volume three weeks after onset of Zol treatment (Figure 3A), BMD was significantly increased in the total skeleton, lumbar vertebrae, distal femur, and proximal tibia in OVX-Let-Zol mice relative to estrogen-replete (sham-PBS), partial estrogen-deprived (sham-Let, OVX-PBS), and total estrogen-deprived mice (OVX-Let) (Figure 4D-4G), confirming that the drug’s anti-resorptive effect persisted throughout the study. Importantly, the OVX-Let group had a significant reduction in total skeletal BMD at the nine-week time point relative to sham-PBS (Figure 4D), indicating that AI treatment continued to cause significant bone loss over the course of the nine-week study due to estrogen deficiency and its possible role in cancer-induced osteolysis.

In order to directly assess cancer-induced destruction of bone, radiographs were acquired three and five weeks post-tumor inoculation, and X-rays were

---

**Figure 1: Study design. Panel A.** Female BALB/c athymic nude (n=20/group) mice were randomized into five treatment groups 1) sham + vehicle (PBS), 2) sham + letrozole (Let), 3) ovariectomized (OVX) + vehicle, 4) OVX + letrozole, and 5) OVX + letrozole + zometa (Zol). **Panel B.** At four-weeks of age, mice underwent sham surgery or OVX, and drug treatments commenced 24 hours later. After changes in bone volume and microarchitecture were assessed by micro-computed tomography (μCT) three weeks post-surgery, groups were inoculated in the left cardiac ventricle with 1x10⁵ MDA-MB-231 human breast cancer cells. Mice were followed for six weeks for the development of bone metastases and tissues were collected following euthanasia at 13-weeks of age.
carefully examined for radiolucent regions indicative of cancer-mediated osteolysis. Osteolytic lesion area was increased in estrogen deprived OVX-Let mice relative to all treatment groups (Figure 5A, 5B). Lesions were detected in AI-treated OVX mice treated with bisphosphonate (OVX-Let-Zol) (Figure 5A); however, the anti-resorptive effects of Zol drastically reduced the total osteolytic lesion area relative to their estrogen-deprived counterparts (OVX-let) (Figure 5A, 5B). These data were corroborated at the histological level through the quantitation of multinucleated bone-resorbing osteoclasts at the bone-tumor interface in the marrow compartment [27]. Osteoclast numbers were increased in OVX-let mice relative to all groups, and Zol treatment reversed this heightened state of osteoclastogenesis (Figure 6A), in line with the drug’s ability to induce osteoclast apoptosis [28].

Having confirmed effects on bone, a primary aim of the study was to evaluate how these AI- and Zol-induced changes to the bone microenvironment could influence tumor progression in the absence of direct inhibition of tumor growth through manipulation of ER signaling. Use of the MDA-MB-231 triple-negative human breast

Figure 2: Impact of ovariectomy (OVX) and aromatase inhibitor (letrozole; Let) on circulating 17β-estradiol and on uterine atrophy in nude mice. Four-week female athymic nude mice underwent OVX or sham surgery and were treated with vehicle or aromatase inhibitor (letrozole, Let; 10μg/day) ±bisphosphonate (zoledronic acid, Zol; 5μg/kg 3x/week; n=20/group). Panel A. Serum was collected via retro-orbital puncture at baseline and three weeks after sham/OVX surgery and commencement of drug treatments. Serum 17β-estradiol was measured by immuno-assay (Calbiotech) as per manufacturer protocol, and results are expressed as % of baseline. Panel B. At the termination of the study nine weeks post-surgery, uteri were dissected and weighed. Results are expressed as mean ±SEM and differences were determined by one-way ANOVA with Tukey’s multiple comparisons test where *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001.
Figure 3: Bone volume and microarchitecture were compromised in nude mice after three weeks of estrogen deprivation treatment. Three weeks after OVX/sham surgery and the commencement of drug treatments, mice were anesthetized with isoflurane and bone microarchitecture was assessed in the proximal tibia by micro-computed tomography (μCT40; SCANCO Medical AG). Panel A. Trabecular bone volume (BV/TV), Panel B. connectivity density (1/mm³), Panel C. trabecular number (1/mm), Panel D. trabecular separation (mm), Panel E. trabecular thickness (mm), and Panel F. structure model index are expressed as mean ±SEM and differences were determined by one-way ANOVA with Tukey’s multiple comparisons test where *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. Panel G. Representative reconstructed images of μCT scans showing trabecular bone at the proximal tibia were selected with a BV/TV % most representative of the group mean.
Figure 4: Changes in body composition and bone mineral density (BMD) in estrogen deficient tumor-bearing nude mice. Three weeks after the beginning of surgery and drug treatments, groups were inoculated in the left cardiac ventricle with $1 \times 10^5$ MDA-MB-231 human breast cancer cells and followed for six weeks for the development of bone metastases. **Panel A.** Body weight was measured weekly. **Panel B.** Lean mass, **Panel C.** fat mass, **Panel D.** total body BMD, **Panel E.** BMD of the lumbar vertebrae (L4-L6), **Panel F.** distal femur BMD, and **Panel G.** proximal tibia BMD were measured at baseline, six weeks, and nine weeks after the beginning of treatments by dual energy X-ray absorptiometry (DXA). Data are expressed as mean % of baseline ±SEM, and differences were determined by two-way ANOVA with Tukey’s multiple comparisons test at week nine where *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001.
cancer cell line permitted this bone-centric objective. Tumor burden in OVX-Let mice was measured at sites of skeletal metastases in histological sections, and total tumor area (mm²) was significantly increased relative to all groups (Figure 6B-6E). Trabecular bone appeared intact in OVX-Let-Zol mice despite the presence of tumor cells (Figure 6E). The overall reduction in tumor area in Zol-treated mice relative to OVX-Let mice (Figure 6D) is likely attributed to the prevention in osteoclastic bone resorption and its feed-forward effect on osteolytic cancer metastases.

Bisphosphonates improved muscle function in AI-treated OVX mice independent of muscle mass

Whole muscle contractility of the extensor digitorum longus (EDL) was measured at the termination of the study to evaluate the potential role of bone loss on muscle dysfunction in a state of AI-induced estrogen deprivation. Estrogen-replete mice with bone metastases (sham-PBS) had a reduction in muscle specific force of the EDL relative to non-tumor age-matched controls, and this reduction reached statistical significance when mice were ovariectomized (OVX-PBS) (Figure 7A). Addition of letrozole to OVX tumor-bearing mice (OVX-Let) led to a further reduction of muscle specific force production of the EDL, reaching statistical significance relative to both tumor and non-tumor and tumor-bearing sham-PBS mice (Figure 7A). This deleterious effect on muscle function in OVX-Let mice was partially reversed by the prevention of osteoclastic bone resorption through zoledronic acid treatment (OVX-Let-Zol) (Figure 7A). Observed changes in muscle specific force production were independent of changes in EDL muscle mass because force production measurements were corrected for size and weight of the

Figure 5: Osteolytic bone metastases assessed by radiography in estrogen deficient nude mice. Panel A. Osteolytic lesions were measured in anesthetized mice in prone position on d23 and d32 post tumor inoculation using a digital X-ray imager (Kubtec) at 2.7x magnification. Lytic lesion area is reported as total lesion area (mm²) per animal in hind limb and forelimb long bones. Panel B. Representative X-rays showing radiolucent lytic lesions (arrows) were selected with lesion areas most representative of the group mean.
Figure 6: Histological assessment of tumor-bearing bone of estrogen deficient nude mice. Panel A. Tartrate-resistant acid phosphatase (TRAP)-positive multi-nucleated cells were quantitated at the bone-tumor interface in mid-sagittal sections of the tibia and expressed as number of osteoclasts per mm of interfacing surface (OcN/mm). Panel B. Mid-sagittal sections were stained with hematoxylin and eosin (H&E) and total tumor area was measured in the tibia, femur and humerus at 10x magnification. Tumor area is expressed as the combined total tumor area per animal (mm²). Panel C. Representative histological images (H&E) showing tumor cells (T) in the distal femur and proximal tibia were selected with tumor areas most representative of the group mean. Differences were determined by one-way ANOVA with Tukey’s multiple comparisons test where *p<0.05 and ***p<0.001.
EDL [29]. Furthermore, hind limb muscles including the EDL, tibialis anterior, gastrocnemius, and soleus collected at the termination of the study in cancer-bearing mice were similar between treatment groups (Figure 7B-7E), indicating that deficits in muscle specific force production in this study can likely be attributed to functional defects as opposed to muscle atrophy.

**DISCUSSION**

The estrogen-replete and estrogen-deficient bone niches differ greatly as host environments for disseminated cancer cells due to the acute sensitivity of bone and marrow cells to changes in endocrine status. Estrogen acts directly on bone cells to regulate the

![Figure 7: Ex vivo contractility of the EDL muscle. Panel A. Ex vivo muscle specific force of the extensor digitorum longus (EDL) muscle was measured in tumor and non-tumor bearing mice. Data are expressed as mean force (±SEM) normalized to muscle size, and differences were determined by two-way ANOVA with Tukey’s multiple comparisons test performed at 150Hz where *p<0.05 and ****p<0.0001. Panels B-E. Muscles of the hind limb were dissected and weighed, including the EDL, tibialis anterior, gastrocnemius, and soleus. Differences were determined by one-way ANOVA with Tukey’s multiple comparisons test where *p<0.05.](#)
lifespan of both osteoclasts and osteoblast, and inhibits T-cell production of inflammatory cytokines, which can further drive osteoclast activation and bone resorption [22, 30]. Increased bone resorption has been demonstrated in preclinical models, including OVX, to accelerate cancer progression in bone [30-32] presumably via release of matrix-derived growth factors, (e.g., TGFβ, IGF, FGF, PDGF), which stimulate tumor growth and expression of osteolytic factors that perpetuate a feed-forward cycle of bone destruction [20]. Using an ER-negative breast cancer cell line to avoid direct tumor growth inhibitory effects, our studies support the postulate that estrogen depletion by AI treatment alters the bone microenvironment in ways that can indirectly promote cancer cell homing, growth, and/or an osteolytic phenotype in bone. The assertion that AI-induced bone loss increased metastatic tumor growth was further supported by the finding that blockade of bone resorption by zoledronic acid reduced tumor burden in bone.

Direct anti-cancer effects of bisphosphonates have been pursued with relatively little evidence that physiologically relevant doses can directly elicit cancer cell apoptosis [33, 34]. Although direct anti-tumor effects of bisphosphonates have been shown in vitro [34], their anti-cancer activity in vivo continues to be attributed to indirect effects via inhibition of osteoclastic bone resorption [30]. Recent clinical reports have demonstrated differential anti-cancer effects of bone-targeted anti-resorptives in breast cancer patients depending on menopausal status. In the AZURE, ZO-FAST, and ABCSG-12 trials, zoledronic acid consistently improved disease-free survival in breast cancer patients, however, this effect was limited to 1) postmenopausal women and 2) premenopausal women undergoing AI therapy treatment (chemical menopause) [35-37], suggesting that the anti-tumor effects of zoledronic acid were reserved for estrogen deficient populations in a high bone turnover state. In light of our studies and the clinical link between bone loss and cancer progression, it will be important to consider the skeletal health not only of cancer patients undergoing AI therapy, but of patients undergoing any therapeutic intervention known to adversely affect skeletal health (e.g., GnRH agonists, glucocorticoids, radiation therapy).

We utilized the triple-negative MDA-MB-231 human breast cancer cell line to assess the impact of the microenvironment on tumor growth in the absence of effects on ER signaling. By contrast, adjuvant AI therapy in the clinical setting is prescribed to breast cancer patients with ER-positive primary tumors [8]. Clinical reports, however, indicate that in many cases ER status at the primary tumor site does not match the ER status of disseminated tumor cells [38], making our model relevant in the setting of advanced disease where metastatic tumor cell ER expression is lost. Use of an ER-positive breast cancer model (e.g., MCF-7) would be useful in determining the relative importance of the benefit of direct tumor growth suppression versus the risk of bone resorption-induced disease progression in the context of AI therapy. Breast cancer mortality results from tumor metastases rather than primary tumor growth [20], and bone is the preferred metastatic destination for breast cancer [39]. In the case of advanced metastatic disease, the growth inhibitory effects of AIs may be overridden by tumor-promoting signals from the bone microenvironment [40]. Thus, the prevention of bone loss in early stage breast cancer patients at the very onset of AI treatment could be of importance.

AI-induced arthralgia and muscle weakness are poorly characterized, yet are often so unmanageable that patients discontinue adjuvant AI therapy [10-14]. The identification of the molecular mechanism(s) underlying AI related muscle dysfunction could be critical in the development of interventions that can restore quality of life and improve drug compliance. In our studies zoledronic acid partially improved muscle function in AI treated mice with bone metastases, suggesting that osteoclastic bone resorption played a role in reduced skeletal muscle contractility in the setting of AI therapy. Recent work reported by our group identified bone-derived TGFβ as the mediator of muscle weakness in mice with bone metastases through the up-regulation of NADPH oxidase 4 production of reactive oxygen species leading to oxidation of the ryanodine receptor (RyR1) calcium channel complex in muscle resulting in SR Ca2+ leak and muscle weakness [25]. Release of bone-derived TGFβ during AI therapy-induced bone loss could have downstream effects on muscle contractility via a similar mechanism, a hypothesis currently under investigation in our laboratory. We speculate that AI-induced muscle weakness is likely multi-faceted in light of the finding that bisphosphonate treatment alone did not restore muscle function to the level of non-tumor control mice. It is possible that AIs elicit direct toxic effects on myocytes, a postulate that has yet to be tested. Selective estrogen receptor modulators (SERMs; e.g., tamoxifen), which interact with the ER and inhibit its activity in breast tissue while preserving bone have also associated with muscle weakness [15], suggesting that inhibition of ER signaling in muscle impacts muscle contractility in the absence of high bone turnover. Furthermore, muscle weakness associated with declining estrogen levels during menopause in healthy women can be rescued by hormone replacement therapy [41-43], providing further proof that ER signaling blockade contributes to muscle weakness in the AI-treated patient. Relevant non-tumor models and in vitro studies will be useful in determining the relative role of bone loss, ER signaling blockade, and potential direct drug toxicities on muscle function following AI and SERM therapy.

In summary, the causes of AI-induced musculoskeletal complications and the consequences of AI-induced bone loss are poorly characterized. Bone-
derived factors released during an elevated state of osteoclastic bone resorption are known to have adverse effects on muscle function and can alter the bone microenvironment to favor breast cancer cell progression and perpetuate osteolysis. Our studies demonstrated that modulation of the bone microenvironment impacted tumor growth locally and muscle function systemically in AI treated mice. These findings emphasize the importance of considering the musculoskeletal health of cancer patients when selecting estrogen deprivation treatment options and the need to further investigate non-estrogenic therapeutic agents that can improve musculoskeletal outcomes in cancer patients.

**MATERIALS AND METHODS**

**Animals**

The Institutional Animal Care and Use Committee at Indiana University approved animal protocols for these studies in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Three-week female athymic nude mice were purchased from Harlan Laboratories (Indianapolis, IN) and housed in plastic cages with access to water and mouse chow *ad libitum* and maintained on a 12 hour light/dark schedule at 22 ±2°C. After one week of acclimation, mice were anesthetized with a ketamine/xylazine cocktail and underwent bilateral ovariectomy (OVX) or a sham surgery under sterile conditions. Aromatase inhibitor (letrozole, 10ug/d), zoledronic acid (Zometa; 5μg/kg 3x/week), and vehicle (PBS, 50μl/d) treatments were administered daily via subcutaneous injection 24h after surgery and continued for the duration of the study. Blood was collected by retro-orbital puncture three days prior to surgery (baseline) and three weeks post surgery. Serum 17β-estradiol was measured by ELISA (Calbiotech) and expressed as percent of baseline.

**Bone microcomputed tomography (μCT)**

Bone μCT was performed at the proximal metaphysis of the tibia using a high-resolution imaging system (μCT40; SCANCO Medical AG) on isoflurane-anesthetized mice. Bone μCT scans were acquired using a 17μm³ isotropic voxel size, 55kVp peak X-ray tube potential, 200ms integration time, and were subjected to Gaussian filtration. Trabecular bone microarchitecture was evaluated in the proximal metaphysis of the tibia in a region that began 0.4mm distal to the growth plate and extended distally 1.0mm. A threshold of 170mg HA/cm³ was used to segment bone from surrounding soft tissue. Trabecular bone outcomes included trabecular bone volume fraction (BV/TV; %), trabecular thickness (Tb.th; mm), trabecular number (Tb.N; mm⁻¹), trabecular separation (Tb.Sp; mm), and connectivity density (Conn.D; mm⁻³). Scan acquisition and analyses were conducted in accordance with guidelines for use of μCT in rodents [44].

**Dual energy X-ray absorptiometry (DXA)**

*In vivo* measurement of fat mass, lean mass and bone mineral density (BMD) was performed on anesthetized mice (ketamine/xylazine) using a PIXImus II densitometer (GE Lunar, Madison, WI) calibrated with a phantom of defined density. Body composition and BMD were measured at baseline on the day of surgery, at week six post-surgery, and at the termination of the study (week nine post-surgery), and data were expressed as percent change over time.

**Intra-cardiac inoculation procedure**

Three weeks after OVX and sham surgeries, mice were inoculated in the left cardiac ventricle with MDA-MB-231 tumor cells, as previously described [27]. Briefly, tumor cell inoculation was performed percutaneously into the left cardiac ventricle of anesthetized mice in a supine position with a 26-gauge needle attached to a 1mL syringe containing 1×10⁵ cells suspended in 0.1mL sterile PBS. Visualization of bright red blood entering the hub of the needle in pulsatile fashion was indicative of correct needle placement into the left cardiac ventricle. Mice were followed for the development of osteolytic bone lesions by radiography on days 23 and 32 of the experiment. Osteolytic lesions were visualized in anesthetized mice in prone position using a digital X-ray imager (Kubtec) at 2.7x magnification. Lytic lesion area, reported as total lesion area (mm²) per animal in hind limb and forelimb long bones, was analyzed in a blinded fashion using ImageJ 1.48r software (National Institutes of Health).

**Histology**

Hind limbs were removed from mice at the time of experimental termination, fixed in 10% neutral-buffered formalin for 48h and stored in 70% ethanol. Tibiae, femora, and humeri were decalcified in 10% EDTA for two weeks, processed using an automated tissue processor (Excelsior, Thermoelctric), and embedded in paraffin. Mid-sagittal 4.5μm sections were stained with hematoxylin and eosin (H&E) with orange G and phloxine to visualize new bone, and with tartrate-resistant acid phosphatase (TRAP) to visualize osteoclasts. Total tumor area was measured in H&E-stained mid-sagittal sections of the tibiae, femora, and humeri at 10x magnification without knowledge of experimental groups. Osteoclast cells were quantified in the mid-sagittal sections of tibiae in tumor-bearing hind limbs. Briefly, TRAP-positive multinucleated cells were quantified at 40x magnification along the perimeter of the tumor where the cancer cells interfaced directly with bone surfaces. Data were expressed as number of osteoclasts.
per mm of tumor-bone interface (OcN/mm), as previously described [27]. All sections were viewed on a Leica DM LB compound microscope outfitted with a Q-Imaging Micropublisher Cooled CCD color digital camera (Nuhsbaum Inc., McHenry, IL). Images were captured and analyzed using BioQuant Image Analysis Software version 13.2 (BIOQUANT Image Analysis Corporation, Nashville, TN).

**Measurement of muscle specific force**

*Ex vivo* contractility of the extensor digitorum longus (EDL) muscles was determined as previously described [25]. Briefly, EDL muscles were dissected from hind limbs and stainless steel hooks were tied to the tendons of the muscles using 4-0 silk sutures and the muscles were mounted between a force transducer (Aurora Scientific) and an adjustable hook. The muscles were immersed in a stimulation chamber containing O₂/CO₂ (95/5%) bubbled Tyrode solution (121 mM NaCl, 5.0 mM KCl, 1.8 mM CaCl₂, 0.5 mM MgCl₂, 0.4 mM NaH₂PO₄, 24 mM NaHCO₃, 0.1 mM EDTA, 5.5 mM glucose). The muscle was stimulated to contract using a supramaximal stimulus between two platinum electrodes. Data were collected via Dynamic Muscle Control/Data Acquisition (DMC) and Dynamic Muscle Control Data Analysis (DMA) programs (Aurora Scientific). The force–frequency relationships were determined by triggering contraction using incremental stimulation frequencies (0.5ms pulses at 1–150 Hz for 350ms at supra-maximal voltage). Between stimulations the muscle was allowed to rest for 3 min. At the end of the force measurement, the length and weight of the muscle was measured. To quantify the specific force, the absolute force was normalized to the muscle size calculated as the muscle weight divided by the length using a muscle density constant of 1.056 kg/m³ [29]. The investigators were blinded to treatment of subjects.

**Statistical analyses**

Differences were determined by one-way or two-way ANOVA, as appropriate, with Tukey’s multiple comparisons test (GraphPad, Prism 6.0f). Results are expressed as mean ±SEM and *p*<0.05 was considered significant.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.

**GRANT SUPPORT**

This work was supported by the Department of Defense Breast Cancer Research Program BC134025 (LEW) and BC043416 (WMK).

**REFERENCES**


